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Abstract 
Title of the abstract:   
Study of the frequency and distribution of IL 28B polymorphisms in hepatitis C virus 
infected patients and their association with virological markers and treatment response 
Department: Department of Clinical Microbiology 
Name of the candidate: Dr. Pragya Ranjan 
Degree and subject: M.D. Microbiology 
Name of the guide: Dr. Priya Abraham 
Keywords: Hepatitis C virus, IL 28B polymorphism, Interferon, Ribavirin, Sustained viral 
response, Rapid viral response 
Objectives: 
The objective of this study was to determine the frequency and distribution of IL 28B 
polymorphisms in hepatitis C virus infected patients and their impact on treatment response 
in genotype 1, 3 and 4 infections. We also evaluated the association of other host and viral 
factors with sustained virological response. 
Methods: 
Fifty seven hepatitis C virus infected patients (genotype 1=12, 3=43 and 4=2) on treatment 
with interferon (standard/pegylated) and ribavirin were recruited. DNA was analyzed for the 
IL 28B polymorphisms using PCR- RFLP (CC, CT and TT for rs12979860 and TT, GT and 
GG for rs8099917).  Bidirectional sequencing was performed on a subset of samples for 
verification of PCR-RFLP results. Information on age, weight, height, diabetic status, pre-
treatment viral load and alanine aminotransferase levels was obtained from clinical records.  
Results: 
The frequency distribution of rs12979860 CC/CT/TT genotypes was found to be 60%, 33% 
and 7% respectively. For rs8099917 genotype, the TT/GT/GG distribution was 72%, 23% 
and 5% respectively. Of the 57 patients recruited, 34 completed follow up during the course 
of the study. Sustained viral response was seen in 56% of these cases (57% in genotype 1 and 
54% in genotype 3). The CC genotype at rs12979860 loci was found to be associated with 
sustained viral response (P value=0.012) and rapid viral response (P value=0.017). No 
association was found between rs8099917 polymorphism and treatment response.  
Age, gender, body mass index, diabetic state, baseline viral loads, pre-treatment alanine 
aminotransferase levels and treatment modality were not found to be associated with 
sustained viral response. Rapid viral response was found to be predictive of sustained viral 
response (P value=0.005). 
Conclusion:  
The CC genotype at rs12979860 loci was found to be associated with sustained viral response 
and rapid viral response.  
. 
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INTRODUCTION 
 
Hepatitis C virus (HCV) is an enveloped, single stranded RNA virus belonging to the family 
Flaviviridae. It is a common cause of post transfusion hepatitis in the resource poor settings. 
HCV infection is a global health problem with a worldwide prevalence of  around 2-3% (1), with 
more than 185 million seropositive people worldwide (2). India has over 10 million HCV 
seropositive individuals (3), the disease being largely spread by blood transfusion and unsafe 
injection practices (4). Spontaneous resolution occurs in about 15 to 40% of acutely infected 
individuals while in the rest chronic infection is established. Chronic hepatitis C shows a variable 
clinical outcome ranging from chronic hepatitis, liver cirrhosis, end-stage liver failure, and 
occasionally hepatocellular carcinoma, which is dependent on an array of host and viral factors 
(5).  
Genomic heterogeneity has led to the classification of HCV into various genotypes and subtypes 
(6). HCV genotypes do not differ in transmissibility or level of replication but are largely 
different in their response to interferon-based therapies, thus impacting the duration of treatment 
needed. There is a huge geographic variation in the distribution and prevalence of HCV 
genotypes globally. The predominant genotype in the western hemisphere is genotype 1, whereas 
genotype 3 is the commonest in the Indian subcontinent, followed by 1 and 4 in that order. The 
largest study from this country (7) found that genotype 3 accounted for 64% of all HCV 
infections , followed by genotype 1 which was 25%.  
Detection of antibodies against HCV indicates exposure to the virus. Viral load testing is 
necessary to establish the presence of active infection. Treatment becomes crucial keeping in 
view the chronic nature of the infection and accompanying complications. Antiviral therapy 
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helps in preventing both hepatic as well as extrahepatic sequelae of infection. Currently, 
pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care therapy for chronic 
hepatitis C, administered for either 48 weeks (genotypes 1 and 4) or 24 weeks (genotypes 2, 3, 5 
and 6). However, treatment is expensive and is associated with significant adverse effects, which 
may be severe enough to lead to premature discontinuation of treatment. This necessitates serial 
monitoring of viral load in patients on therapy to assess and prognosticate the treatment 
response. The recommended time points of monitoring are: 
Rapid viral response (RVR) at 4 weeks 
Early viral response (EVR) at 12 weeks 
End of treatment response (ETR) at 24/48 weeks, based on genotype 
Sustained viral response (SVR) at 24 weeks after ETR 
SVR rates of 40–50% are seen with genotype 1 HCV, and upto 80% in genotypes 2 and 3 
infections (8). 
Since treatment is expensive and often accompanied by several adverse effects, the significance 
of viral and host factors which impact on severity of disease and response to treatment becomes 
immense. Age<40 years, female gender, Caucasian race, body weight <85 kgs, absence of 
diabetes mellitus, absence of steatosis on liver biopsy, fibrosis score on liver biopsy ≤2 are 
established factors which predict a good response to therapy (9). 
Recently  several  genome  wide  association  studies  have  shown  that  single  nucleotide  
polymorphisms (SNPs)  within  or  adjacent  to  the  IL28B  gene  (rs12979860  and  rs8099917)  
are  strongly  associated  with response to PEG-IFN/RBV therapy in genotype 1 infections (10–
12). The IL28B gene located on chromosome 19 codes for Interferon λ3 which induces antiviral 
and anti proliferative activity in many cell types  and upregulates interferon stimulated genes 
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(ISGs) (13). The possible genotypes at rs12979860 are CC, CT and TT, while those at rs8099917 
are TT, TG and GG. The CC genotype of rs12979860 and TT of  rs8099917  have  been  shown  
to  be  associated  with  a better  treatment  response. These  polymorphisms show a  marked 
differential racial distribution (10) explaining much of the observed differences  in the  response 
rates to treatment  in different ethnicities. Its association with spontaneous clearance of HCV 
infection has  been shown  irrespective  of  the  viral  genotype (14). The  association  with  
virological  response  has  also  been found in  HCV  genotype 4 (15). The association of IL28B 
polymorphisms with response to treatment in HCV genotype 2 and 3 infections have remained 
controversial. Studies have shown conflicting results. However, the largest meta analysis by 
Jiménez-Sousa et al. found significant associations of rs12979860 and rs8099917 
polymorphisms with treatment response in genotypes 2 and 3 infected patients, but the strength 
of association was three fold lower than that for genotypes 1 and 4 (16).  
In 2012, Sivaprasad et al. (17)  studied the distribution of genotype and allelic frequency of 
IL28B rs12979860 polymorphism in 220 healthy uninfected controls in Andhra Pradesh, India, 
and found that the frequency of CC genotype (59%) was significantly higher compared to CT 
(34.09%) and TT (6.81%).  Thereafter, Gupta and colleagues (18) from New Delhi analysed the 
rs12979860 SNP in 356 patients infected with HCV genotype 3 and found the CC genotype to be 
an independent strong predictor of RVR and SVR.  Another group from Kolkata (19) has found 
genotypes CC at rs 12979860 and TT at rs8099917 to be strongly associated with SVR in their 
study on 83 HCV genotype 3 patients. However, association of these polymorphisms with 
genotype 1 has not been looked at in both the studies. 
This study aims to determine the frequency and distribution of IL28B gene polymorphisms in 
patients with chronic HCV infection harbouring genotype 1 in addition to 3, and to study the 
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association of these SNPs with response to IFN based treatment. It would also study the 
correlation of other host factors like age, gender, body mass index, diabetes and baseline alanine 
aminotransferase (ALT) levels with treatment response. 
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AIM 
To study the frequency and distribution of IL28B polymorphisms in hepatitis C virus infected 
patients and their association with virological markers and treatment response. 
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OBJECTIVES 
1. To study the frequency and distribution of IL28B polymorphisms in hepatitis C virus infected 
patients. 
2. To study and compare sustained viral response rates in hepatitis C virus genotype 1 and 3 
infections. 
3. To  study  the  association  of  IL28B  polymorphisms  with sustained viral  response  after  
treatment  in hepatitis C virus genotype 1 and 3 infected patients. 
4. To study the association of other factors like age, gender, body mass index, diabetes, pre-
treatment viral loads, baseline alanine aminotransferase levels and treatment modality with 
sustained virological response. 
5. To study the association of IL28B polymorphisms with virological response during the course 
of treatment (Rapid viral response, Early viral response, End of treatment response). 
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REVIEW OF LITERATURE 
Ever since its discovery in 1989 as the causative agent of transfusion associated non-A non-B 
hepatitis, HCV has been increasingly recognized as a global health concern. First thought to be a 
trivial infection limited to the intravenous drug users and blood product recipients in developed 
countries, it is now established as the predominant cause of post transfusion hepatitis and chronic 
liver disease worldwide, more so in the developing parts of the world. Owing to the tendency of 
HCV to cause persistent infection, it is associated with a wide disease spectrum ranging from 
chronic hepatitis, liver cirrhosis, end-stage liver failure, and occasionally hepatocellular 
carcinoma.  
1. Epidemiology 
 
1.1 Global burden: 
HCV infection has a worldwide distribution, affecting persons of all ages, races, genders and 
regions of the world. The global prevalence of the infection is estimated to be 2-3% (1), with 
more than 185 million seropositive people worldwide (2). HCV accounts for more than 350,000 
deaths annually, most of which are attributable to liver cirrhosis and hepatocellular carcinoma 
(20). Prevalence higher than the global average has been reported from Africa (3.2%) and the 
Middle East (4.7%) (1). 
1.2 Indian Scenario: 
HCV infection is an important emerging cause of liver disease in India. Blood transfusion and 
unsafe injection practices are believed to be two major routes of spread of the virus in our part of 
the world (4). There is a dearth of large community based studies to estimate the real burden of 
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the infection in India, however, in the largest such study by Chowdhury and colleagues from 
West Bengal (21), the prevalence of HCV antibody was found to be 0.87% (26 of 2973 samples). 
HCV RNA was detected in 81% of those who were anti-HCV positive.  With our teeming 
population, this would translate to more than 10 million HCV seropositive individuals across the 
nation (3), of whom 8 million may be viraemic. 
A study on a rural population in Maharashtra (n=1054) found a very low prevalence of 0.09% 
(22), whereas two studies from Andhra Pradesh found the prevalence to be 1.4% and 2.02% 
respectively (23,24). 
Seroprevalence in voluntary or replacement blood donors has been found to range from 0.7% to 
1.8% (25). What is worrisome is the very high prevalence of 55.3% and 87.3% in  professional 
donors as per two studies in western India (26,27). High prevalence has also been reported from 
other high risk groups for the infection; 16.7% to 21% among thalassemia patients, 23.9% 
among multiply transfused hemophilia patients, 9.93% in hemodialysis patients and 92% in 
intravenous drug users in the Northeast (3).  All of this emphasizes the need for stringent blood 
banking and injection practices throughout the nation. 
2. Hepatitis C Virus 
2.1 Classification and Taxonomy: 
Owing to its structure, genomic organisation and replication, HCV has been classified as a 
member of the family Flaviviridae, along with other related positive-stranded RNA viruses. The 
virus, however, is distinct enough to merit classification within a separate genus, Hepacivirus, 
which gets its name from the Greek  word „hepatos‟ meaning liver . The other two genera within  
Flaviviridae, genus Flavivirus (e.g., Japanese encephalitis virus, dengue  viruses and  yellow  
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fever  virus) and genus Pestivirus (e.g., bovine viral diarrhoea virus and  classical swine fever 
virus), differ from HCV in the organization of  certain structural proteins (28). 
2.2 Structure of the virus:  
HCV is an enveloped, 9.6 kilobases long positive sense single-stranded RNA virus (28). Like the 
other members of family Flaviviridae, its genome has one large open reading frame (ORF) 
which accounts for over 95% of the sequence. The ORF encodes a single large polyprotein, 
about 3010 amino acids long, which undergoes post-translational modifications to yield various 
viral proteins. Flanking the ORF at both 5´- and 3´- ends are highly conserved untranslated 
regions (UTRs), which mediate crucial steps in viral replication. 
2.2.1 Untranslated regions 
About 341 nucleotides long, the 5′UTR is a highly conserved region (29). It has an 
approximately 300-nucleotide long segment, known as “internal ribosomal entry site”(IRES),  
that mediates direct binding of the 40S host ribosome subunit to the viral genome and facilitates 
the process of translation (30). 
The 3′UTR contains a 40 nucleotide long variable region, a poly U/UC tract of heterogeneous 
length, and a highly conserved 98-nucleotide long sequence, designated the X tail or 3′X(31). 
Parts of this 3′X tail form a “kissing loop” interaction with the NS5B  coding  region, which 
along with a 33 consecutive U residue segment in the poly-U/UC tract, is absolutely necessary 
for viral RNA replication (32). 
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2.2.2 Polyprotein 
The ORF encodes a polyprotein that is processed into 10 proteins. The polyprotein can be 
functionally divided into three segments. 
A. The NH2-terminal region, comprising the structural proteins (core and  the  envelope 
glycoproteins, E1 and E2) 
B. The central region including two proteins (p7 and NS2) which are essential  for virion 
production but are not required for viral RNA replication; and 
C. The COOH-terminal region, which consists of five nonstructural proteins (NS3, 
NS4A, NS4B, NS5A, and NS5B) that are needed for RNA replication. 
 
Figure 1.Organization of the HCV genome and polyprotein 
                                  
2.2.2.1 Structural proteins 
First product of the polyprotein is the highly basic core  protein, C, which binds with RNA to 
form the nucleocapsid (33). Next two domains in the polyprotein are processed into two 
glycoproteins, E1 and E2. These transmembrane proteins are essential for initial viral attachment 
to host cells, thus facilitating cell entry at specific steps (34). E2 contains a hypervariable region, 
whose rapid evolution during the course of an infection prevents recognition by antibodies (35). 
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2.2.2.2 p7 and NS2 proteins 
These two proteins do not play a role in RNA replication but are crucial in virion morphogenesis 
and release. p7 (formerly NS2A) functions as a viroporin, transporting calcium ions from  
endoplasmic reticulum into the cytoplasm, thereby representing a possible therapeutic target 
(36). 
The NS2 (formerly NS2B) protein has a protease domain that mediates cleavage at the NS2/NS3 
junction, essential for the production of infectious virions(37). 
2.2.2.3 Nonstructural proteins   
All the five nonstructural proteins (NS3, NS4A, NS4B, NS5A, and NS5B) are involved in RNA 
replication. The amino-terminal of the NS3 protein possesses serine protease activity and 
carboxy-terminal has RNA helicase activity. The protease is responsible for cleavage of the 
NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B junctions during processing of the polyprotein. 
The NS4A protein functions as a cofactor for the NS3 protease. NS4B is thought to play an 
important role in modifications of endoplasmic reticulum membrane, and thus in the organisation 
of the membrane-bound replication complex. A part of the NS5A phosphoprotein, known as 
interferon sensitivity determining region (ISDR), is believed to determine response to IFN based 
therapy. NS5B encodes a viral RNA-dependent RNA  polymerase (RdRp), which is a key 
component for HCV replication (38). 
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Figure 2.Genomic structure of hepatitis C virus, Adapted from Lindenbach and Rice  (38) 
 
2.3 Replication: 
Life cycle of HCV begins with attachment and internalization of the virus into the host cell, 
which is mediated by viral envelope glycoproteins E1 and E2. A number of host cellular 
receptors such  as  CD81, DC-SIGN,  SR-BI  claudin-1, and occludin are believed to be 
necessary for this process. After attachment and entry, uncoating of the nucelocapsid occurs, 
leading to release of the viral RNA into host cytoplasm. Being positive stranded,  HCV RNA  
acts  as  messenger  RNA  (mRNA) and translation of the polyprotein is initiated following 
ribosomal binding mediated  by  the  HCV  IRES  domain. This is followed by a number of 
cleavages of the polyprotein by both cellular and viral proteases, resulting in the production of  
various structural and non-structural proteins, as outlined in the previous section. Following 
cleavage, the core protein stays in cytoplasm, while E1 and E2 are secreted into lumen of 
endoplasmic reticulum. The non structural proteins assemble to form a membrane-bound 
replication complex, where the viral NS5B RdRp facilitates the synthesis of a negative-stranded 
RNA intermediate. This subsequently serves as a template for synthesis of positive-stranded 
genomic RNA. Following this, RNA, along with the core, E1 and E2 proteins gets packaged into 
27 
 
new viral particles.  After maturation and assembly, newly produced virions are released from 
the host cell through the secretory pathway. 
2.4 Genetic diversity: 
2.4.1 Quasispecies variation 
The replication process of HCV is highly prone to errors and mutations due to its rapidity and 
lack of proof-reading by the NS5B RNA polymerase. This, coupled with immunologic selection, 
leads to  accumulation of a multitude of closely related but distinct HCV variants within an 
infected individual, known as a quasispecies (39). This heterogeneity of the viral population may 
rapidly select treatment-resistant clones,  thus  possibly  reducing  treatment  efficiency  of  the  
new  direct acting antiviral (DAA) drugs recently approved for treating HCV infection (40). 
2.4.2 HCV genotypes 
In addition to quasispecies variation that occurs in a single infected individual, there is also 
tremendous heterogeneity among sequences of HCV isolates from different individuals. This has 
led to their classification into genotypes and subtypes. Based on sequence homologies, 
phylogenetic studies have shown that there are seven genotypes categorized 1 through 7 and 67 
confirmed subtypes named with the letters a, b, c and so on following the genotype Genotype 7 
was long considered a provisional genotype represented by a single strain, but has now been 
confirmed as a separate genotype (6). Genotyping is usually done by sequencing either the 
5′UTR/core, NS3 or of the NS5b region of HCV genome. Across genotypes, the diversity at the 
nucleotide level is estimated to be about 30% (35,41). Within individual genotypes, subtypes 
differ by at least 15% in nucleotide  sequence  identity  within  the  core/E1  and  NS5B  regions 
(6). HCV genotypes do not differ in transmissibility or level of replication but are largely 
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different in their response to interferon-based therapies, thus impacting the duration of treatment 
needed. 
2.4.2.1 Global distribution of HCV genotypes 
The geographical distribution of different genotypes is quite distinct. Genotype 1 is found to be 
the commonest genotype worldwide with a wide distribution in USA and northern Europe 
(35,41). Genotypes 2 and 3 are also found worldwide, with a higher prevalence in Europe, North 
America, and Japan (42). HCV genotype 3 infection is endemic in Southeast Asia and the Indian 
subcontinent. It is also particularly prevalent in intravenous drug users in the USA and Europe. 
Genotype 4 infections are mainly prevalent in North Africa and Middle East. Genotype 5 appears 
to be confined to South Africa and genotype 6 to intravenous drug users in Southeast Asia and 
more recently in Australia. Genotype 7 has been reported from a single case in central Africa. 
(35,41,43) 
2.4.2.2 Distribution of HCV genotypes in India 
There are a few studies which have attempted to establish the distribution of HCV genotypes in 
the country. In the largest such study by Christdas et al.(7), spanning over a decade (2002-2012) 
and including 451 patients from various parts of the Indian subcontinent, genotype 3 was found 
to be the most predominant (63.85%), followed by genotype 1, 4 and 6 (25.72%, 7.5% and 2.7% 
respectively). Genotype 2 was found in only one patient from Northeast India, and genotype 5 in 
none. (As is mentioned in the table below, genotype 2 has been infrequently reported by other 
authors, while genotype 5 is yet to found in our part of the world.) Genotype 1 was commoner in 
South India, while genotype 3 was more prevalent in Eastern and Northeastern parts of the 
country. Genotypes 4 and 6 appeared to be restricted geographically to the Southern and North-
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Eastern parts of the country respectively, which has been published previously as well (44,45). 
Recombinant strains of genotype 1 and 2 were isolated from two patients. 
In another study on 398 patients from North and Central India (46), the findings were similar. 
Genotype 3 was the commonest genotype, seen in 80.2% patients, followed by genotype 1 in 
13.1% patients. Genotypes 4 (3%) and 2 (2.5%) were rare. There were no cases of genotype 5 
and 6 infections. Five patients showed infection with mixed genotypes. 
The following table summarizes the various studies estimating the distribution of HCV 
genotypes throughout the country.  
Table 1.Distribution of HCV genotypes in India 
Author Year N Distribution of genotypes (in %) 
   1 2 3 4 6 Misc. 
Christdas et al.(7) 2013 451 25.7 0.002 63.9 7.5 2.7 0.004
# 
Chakravarty et al.(47) 2013 31 29 9.6 61.2 - - - 
Chakravarty et al.(48) 2011 71 31 5.6 63.4 - - - 
Hissar et al.(46) 2006 398 13.1 2.5 80.2 3 - 1.3
# 
Chaudhuri et al.(49) 2005 420 10.2 3.8 79.8 - - 6.2
#* 
Singh et al.(50) 2004 36 13.8 5.5 66.6 2.7 - 11.1
* 
Raghuraman et al.(51) 2003 90 18.9 1.1 62.2 5.6 - 12.2
* 
Chandra et al.(23) 2003 18 66.7 - 33.3 - - - 
Das et al.(52) 2002 153 24.2 2 69.9 3.9 - - 
Amarapurkar et al.(53) 
Valliammai et al.(54) 
2001 
1995 
61 
24 
21 
87.5 
25 
- 
54 
12.5 
- 
- 
- 
- 
- 
- 
Genotype 5 has not been reported in any of these studies. 
# mixed infection              * untypeable infection 
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3. Natural history of the disease 
3.1 Acute Hepatitis C and spontaneous clearance 
HCV can cause both acute and chronic hepatitis. Acute infection with HCV is mostly 
asymptomatic. HCV RNA is detectable in majority of patients within 1-2 weeks and is followed 
by a rise in serum transaminases by 2-8 weeks. About 25 to 30% of patients with acute HCV 
infection develop symptoms within 3-12 weeks of exposure to the virus (average 7 weeks). Anti-
HCV seroconversion occurs near the onset of symptoms. However anti-HCV is unreliable in the 
diagnosis of acute HCV infection as up to 30% of patients will test negative at the onset of 
symptoms because of delayed seroconversion. Almost all patients will eventually develop anti- 
HCV, though titres may be low in the context of immunosuppression (55). 
An estimated 15-40% patients spontaneously clear the virus, becoming HCV RNA negative, 
while majority infected with HCV will go on to develop chronic infection. 
3.2 Chronic Hepatitis C and progression of fibrosis 
Persistence of HCV RNA for more than 6 months after onset of infection defines chronic 
hepatitis C. Age at acquisition of infection, sex, race, immune status of the patient, co-infections, 
along with other host and viral factors influence chronicity of the infection (5). The early phase 
of the infection is marked by appearance of HCV RNA, followed by rise in serum transaminases. 
It must be noted that in the time period of evolution from acute to chronic hepatitis, HCV RNA 
and enzyme levels can fluctuate remarkably. Once the infection gets persistent, viral load tends 
to stabilize. Spontaneous resolution of chronic infection is unusual. Fatigue, abdominal 
discomfort, nausea, and poor appetite are the most common symptoms seen (55). The disease 
may remain clinically silent for decades. However, hepatocellular inflammation and fibrosis 
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continues, leading to progressive liver disease. The rate of progression of the disease is again 
determined by a multitude of modifiable and non modifiable factors. Progressive hepatic fibrosis 
may lead to cirrhosis and decompensated liver disease. Such patients are at highly increased risk 
of hepatocellular carcinoma, with 1 to 4% of patients developing this complication each year 
(56). It usually takes more than two decades of infection for these long term complications to 
develop, unless accelerated by coexistent factors. 
 
4. Immune Response to HCV Infection 
Viral infection triggers an array of intracellular events that lead to the development of an 
antiviral state in the infected cell and the surrounding tissue. After viral entry into the host, 
pathogen-associated molecular patterns (PAMPs) in the viral genome are recognised by PAMP 
receptors expressed on the host cell, initiating the host immune response. Retinoic acid inducible 
gene I (RIG-I) and Toll-like receptor 3 (TLR3) are two major receptor pathways triggered by 
Figure 3. Natural history of HCV infection 
Adapted from Mandell, Douglas and Bennett‟s Principles and Practice of Infectious Disease, 7 th edition 
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HCV RNA. This subsequently stimulates interferon stimulated genes (ISGs) inducing 
endogenous interferon (IFN) production, and thus building the initial antiviral defence (57). For 
successful replication and establishment of a persistent infection, HCV develops various 
strategies to evade host immune response. It is the balance between the two which determines 
progression of the disease. 
4.1 Innate Immune response 
4.1.1 Interferons and Interferon Stimulated Genes 
The first response to HCV infection is by the production of endogenous IFN by the infected 
hepatocytes. This begins with TLR-3 and RIG-1 mediated sensing of HCV RNA, which through 
various mediators leads to signalling of IFN regulatory factor 3  (IRF3). This induces the 
transcription of IFN-β, creating an antiviral state in infected and uninfected neighbouring cells, 
via paracrine effects, limiting cell to cell spread (58). IFN-β binds to the IFN-α/β receptor, 
activating the JAK/STAT pathway. This results in induction of IFN stimulated genes (ISGs), 
which have different antiviral properties, such as degradation of viral RNA, inhibition of 
translation and destabilisation of secondary structures of viral RNA.  Some pattern recognition 
and signalling molecules like RIG-I are also ISGs, whose levels markedly increase from low 
basal levels, increasing the sensitivity of downstream signalling in infected tissues, and 
promoting IFN and ISG production. Another ISG, IRF7 stimulates IFN-α production, thus 
diversifying the IFN response, and providing a positive feedback  to ISG expression (57,59). 
The current treatment for HCV capitalises on the IFN- α component of immune response. 
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Figure 4.Molecular processes that signal the host response during HCV infection, adapted 
from Gale and Foy (57) 
 
 
4.1.2 Attenuation of Innate Immune Response by HCV 
HCV is known to employ multiple strategies to attenuate innate IFN response.  
1. The HCV NS3/4A protein, via its protease activity, cleaves two important host adapter 
molecules TRIF and IFN-β promoter stimulator protein 1 (IPS-1), thereby blocking 
TLR3 and RIG-I signalling and hence IRF3 activation. 
2. HCV core protein brings about impairment of JAK/STAT signalling pathway and ISG 
expression. 
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3. HCV NS5A stimulates IL-8 production which inteferes with ISG expression, thus 
antagonizing type I IFN signalling.   
Other than the aforementioned mechanisms, HCV also interferes with  functioning of 
dendritic cells and NK cells, both of which contribute to defence against the virus (59).  
4.2 Adaptive Immune Response  
4.2.1 Humoral Immunity 
Antibodies corresponding to structural and non structural proteins of HCV are detectable in 
about 7 to 8 weeks of infection. These antibodies are neutralizing in nature, differing in their 
breadth and mechanisms of neutralization. The antibodies are isolate specific, and together 
with CD8
+
 T cells contribute to the evolution of HCV quasispecies by exerting selection 
pressure. Lack of temporal relation of these antibodies to viral recovery and demonstration of  
HCV clearance in individuals with agammaglobulinemia led to the belief that humoral 
immune response was neither necessary nor sufficient for viral clearance (59,60). 
However, recent studies have elucidated the role of the neutralizing antibodies in disease 
outcome. Early and rapid induction of these antibodies has been found to lead to spontaneous 
resolution of infection, contrary to the cases of chronic infection, where antibodies were 
either absent or very low in titre in early phase of the infection, thus suggesting a crucial role 
in the outcome of the infection (61). 
4.2.2 Cellular Immunity 
HCV specific CD8
+ 
and CD4
+
 T cell response is known to be critical for HCV clearance. A 
functional CD4
+ 
response is an important factor dictating the fate of HCV infection by 
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production of IL-2 and IFN-γ. Vigorous proliferation of HCV specific CD4+ T cells is 
seen in individuals who clear the virus, in contrast to an impaired or weak response in those 
who progress to chronic disease (62).  
On the other hand HCV specific CD8
+ 
cells are detectable in cases of acute infection 
irrespective of virological outcome. In acute infection some CD8
+ cells show a “stunned” 
phenotype and are unable to produce IFN-γ. However, as CD4+ T cell responses develop 
and viremia declines, this dysfunction resolves and memory cells become  detectable (63). 
In cases of recovery, durable populations of memory T cells are seen. In chronic infections, 
persistent antigenic stimulation along with impaired CD4
+
 T cell function leads to CD8
+
T 
cell exhaustion. This state is marked by loss of CD8
+
 T cell cytotoxic  functions, TNF-α 
production, and eventually IFN-γ production along with dysfunctional memory T cells as 
is often the case in chronic HCV infection (59). 
4.2.3 Evasion of Adaptive Immune Response by HCV 
A lot of theories for persistence of HCV infection are hypothesized, but the following three 
mechanisms have substantial experimental support (60). 
1. Mutational escape of viral epitopes 
The error prone nature of the viral polymerase generates viral variants capable of evading 
cytotoxic T cells and neutralizing antibodies. 
2. Functional anergy of CD8+ T cells 
As discussed in the previous section, HCV specific CD8
+ 
T cells may be anergic or 
functionally impaired in chronic infections. 
3. Regulatory T cell populations 
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Intrahepatic CD8
+ 
T cell populations producing IL-10 are known to occur in chronic 
infections. IL-10 impairs production of IFN-α and downregulates effector T cell 
responses.  
The outcome of HCV infection is depicted in the flowchart below. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.Outcome of HCV infection, Adapted from Gale and Foy (57) 
RIG-1: Retinoic acid inducible gene I             TLR3: Toll-like receptor 3               
 IFN: Interferon                                                ISG: Interferon stimulated genes 
Exposure to HCV 
Viral quasispecies outgrowth/ selection / 
diversification /viral adaptation 
IFN production attenuated:  
 
Attenuation of ISG expression and function 
Alteration of antigen presentation and 
immune cell function 
Persistent infection and evasion of IFN actions 
IFN production/ISG expression 
Viral protein interference with host 
response; host response blocked 
Infection resolved 
 (15-25% of cases) 
Signalling interference 
NS3/4A 
 
NS3 
Acute infection 
Host response triggering 
RIG-1, TLR3 
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5. Diagnosis of HCV infection 
Testing for HCV infection is mainly done for a clinical diagnosis of liver disease in symptomatic 
individuals and as a part of mandatory screening in blood banks for all donors. It is also 
advisable for individuals who are at a high risk for the infection. Guidelines  recommend HCV 
screening in persons with HIV infection, haemophilia, haemodialysis, illicit drug use, recipients 
of blood transfusion or organ transplantation before 1992, children born to HCV infected 
mothers and health care workers after an exposure (64). 
Diagnostic tests for HCV are broadly grouped into serologic assays to detect the presence of 
virus specific antibodies, and molecular tests for detection and quantification of viral RNA and 
genotyping of the virus. 
5.1 Serology 
Detection of HCV specific antibodies is an indicator of infection with the virus and not 
immunity. Immunoassays, based either on enzymatic reactions (Enzyme-linked immunosorbent 
assay, ELISA) or light emission (Chemiluminescence  immunoassay, CLIA) are the standard 
tests used by most diagnostic laboratories. Different generations of HCV ELISA detecting 
antibodies to different recombinant polypeptides have been developed. While the first generation 
ELISA targeted a part of the NS4 region of HCV genome, the second generation included a 
protein derived from NS3 and a part of core (C-22) additionally. The third generation ELISA 
detects antibodies against NS5 as well, and has a high sensitivity of about 97%.  Recombinant 
immunoblot assay (RIBA) can be used as a supplemental test to identify the specific antibodies 
against individual HCV antigens. Some rapid immunoassays have been developed as point of 
care tests for rapid detection of HCV antibody. 
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5.2 Molecular assays 
5.2.1 Detection of viral nucleic acid 
Detection of HCV RNA is necessary to establish active infection, either acute or chronic, as well 
as for monitoring the patients on treatment. Reverse transcription polymerase chain reaction 
(RT-PCR), real time RT-PCR, transcription mediated amplification (TMA), and branched DNA 
testing can be used. Assays that detect nucleic acids can be qualitative or quantitative. While 
qualitative methods may be sufficient for screening in blood banks, quantitative assays are used 
to measure the baseline viral load prior to initiation of therapy, and then at specified time points 
for monitoring of treatment response during the course of therapy. WHO has recommended the 
use of a standard “International Units” (IU) for measurement of the viral RNA instead of viral 
copies. Most contemporary assays have excellent specificities 98 to 99% and sensitivity varying 
from 10 to 50 IU/mL (64). 
5.2.2 Viral genotyping 
Determination of genotype of the infecting virus is necessary to tailor the duration of treatment 
needed, as well as to predict the probability of response. Genotyping can be done by sequencing 
either the 5′UTR/core, NS3 or the NS5b region of HCV genome. A number of assays are 
available for the same and include real time PCR with genotype specific probes and primers, 
reverse hybridization of PCR products onto genotype specific probes coated on solid supports 
(line probe assay), PCR-restriction fragment length polymorphism (RFLP), where the PCR 
products are digested with restriction enzymes, to obtain fragments of varying length depending 
upon the genotype. 
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5.3 IL28B genotyping  
Single nucleotide polymorphisms in the region upstream of IL28B gene (rs12979860 and 
rs8099917) have been found to be strong predictors of response to interferon based therapy. 
These polymorphisms can be detected by PCR-RFLP, direct sequencing or pyrosequencing. 
These polymorphisms can be used to prognosticate treatment, but absence of tools to detect these 
polymorphisms, by no means, impacts the treatment. 
6. Treatment of Hepatitis C 
6.1 Rationale for treatment 
Hepatitis C is a severe infection causing considerable morbidity and mortality globally. The main 
concern associated with the infection is progression to liver cirrhosis and its accompanying 
complications. Patients with chronic infection are at risk of extrahepatic manifestations even in 
the absence of progressive fibrosis, some of which may be severe.  Antiviral treatment is 
necessary to prevent both the hepatic as well as extrahepatic sequelae of infection. Virologic 
cure, marked by sustained lack of viraemia six months after completion of therapy, is associated 
with lessening of liver inflammation, as evidenced by stabilized enzyme levels and decrease in 
the rate of progression of liver fibrosis. Timely treatment has been shown to decrease the 
development of end stage liver disease, need for liver transplantation, hepatocellular carcinoma 
rates and liver related mortality (65). 
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6.2 Drugs used for treatment  
1) Interferon and Ribavirin: 
For the past two decades, recombinant IFN-α has been the key component of treatment for 
chronic HCV infection. Pegylation of IFN-α and its use in combination with RBV has markedly 
improved treatment efficacy, when compared with standard IFN. Combination therapy with 
PEG-INF and RBV has long been the standard of care for chronic HCV infection, given for 
either 48 - 72 weeks (genotypes 1, 4) or 24 - 72 weeks (genotypes 2, 3, 5 and 6) (66). No 
recommendations have been suggested for genotype 7. However, the treatment is expensive and 
is associated with significant adverse effects, some of which may be life threatening. The 
mechanism of action, guidelines for use, response rates, adverse effects and the factors affecting 
response to therapy has been discussed in detail in a later section. 
2) Direct- acting antivirals: 
These new antiviral drugs have lately become established components of treatment regimens for 
chronic HCV infection, especially with genotype 1. Though yet to be introduced in most 
developing nations, these drugs are revolutionizing the treatment of hepatitis C in the developed 
world. With their better response rates and lesser side effects, they might replace IFNs in chronic 
hepatitis C treatment in the next few years (67). The first drugs of this class to be approved were 
telaprevir and boceprevir, both being NS3/4A protease inhibitors. A combination of these drugs 
with PEG-INF and RBV for previously untreated genotype 1 infections showed SVR rates of 
upto 75%. However these drugs are not of great help in cases which have failed previous IFN 
based treatment. Their spectrum of action is limited to genotype 1 and they need to be combined 
with the conventional standard of care therapy. These factors led to the introduction of two 
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newer direct-acting antiviral agents, sofosbuvir, and simeprevir. Sofosbuvir inhibits NS5B RNA-
dependent RNA polymerase, and is thus active against all HCV genotypes. Clinical trials have 
found response rates in various HCV genotypes to vary from 50% to >90%. Simeprevir, a 
second generation NS3/4A protease inhibitor, has shown response rates of about 80% in 
previously untreated as well as treatment failed genotype 1 infections (68). 
7. Interferon and Ribavirin for treatment of chronic hepatitis C 
1) IFN-α monotherapy: 
Even before the identification of HCV, IFN-α was shown to benefit patients with non-A non-B 
hepatitis in 1986 (69). Once the virus was identified and diagnostic tests for it were developed, 
the mechanism of action of IFN and its basis of use was elucidated. IFN-α therapy led to a rapid 
fall in serum viral load, and resolution of the infection. For the entire following decade, 
monotherapy with IFN-α was accepted as the standard of care for chronic infection with HCV. 
However, the sustained response rates were limited to 10 to 25% even after modifications of the 
dosing regimens and duration of treatment (70). Another issue was severe side effects associated;  
asthenia, neutropenia, myalgia, headache, thrombocytopenia, and depression (71). 
2) IFN-α and Ribavirin combination: 
It was by the end of 1990s when RBV, a nucleoside analogue with a broad-spectrum antiviral 
activity, was introduced for the treatment of chronic HCV infection as a combination with IFNα. 
This combination therapy showed not only doubled virologic response rates (35–40%), but also 
improved biochemical and histologic response. 
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(72). In 1998, a large randomized controlled trial on 912 chronic hepatitis C patients showed a 
greater than 20% increase in virological response rate with RBV combination therapy over IFNα 
monotherapy (73). Thereafter this combination therapy became the new standard of care. 
3) Pegylated IFN-α: 
Further improvement in response rates was brought about in 2001 by the introduction of PEG- 
IFN-α in combination with RBV. The covalent attachment of a polyethylene glycol moiety to 
recombinant IFN-α improves the half-life, pharmacokinetic profile and virological response rates 
(74). This led to the change of the dosing regimen from thrice weekly to the more convenient 
once-a-week injection. Using the PEG-INFα and RBV combination, sustained virological 
response (SVR) rates of 40–50% are seen with genotype 1, and ≥80%  in genotypes 2 and 3 (8).   
7.1 Mechanism of action 
7.1.1 Interferon 
Interferons are classified as type I, II and III.  IFN-α/β/ω are classified as type I, IFN-γ as type II 
and IFN-λ as type III interferons. All type I IFNs possess antiviral and immunomodulatory 
activities, but with  varying potencies (75). Current therapy for chronic HCV infection banks on 
the antiviral activity of IFN- α. As has been discussed in the section on innate antiviral response, 
IFN-α acts by induction of ISGs through intracellular cascades, which create antiviral state 
within the cell. It does not inhibit viral replication directly. Apart from the induction of ISGs, it 
also has immunomodulatory effects like activation of NK cells, maturation of dendritic cells, 
induction of cytokine production, prevention of T cell apoptosis and improved antigen 
presentation. It is assumed that exogenously supplied recombinant IFN-α works by the same 
mechanism as endogenous IFN, but with a better effectiveness owing to the higher concentration 
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supplied. The mechanisms by which the virus can evade the action of interferon have been 
discussed in detail in a previous section, and include inhibition of the transcription of interferon 
induced antiviral genes by the HCV core  protein and  inhibition  of  the  interferon  amplication  
loop  by HCV NS3/4A protease (9). 
In contrast to type I IFN which are secreted by all virus infected cells, IFN-γ (Type II) is 
produced by cytotoxic T cells and NK cells and exerts its antiviral action by independent 
pathways leading to inhibition of viral protein synthesis and RNA replication (76). 
Type III interferons (IFN-λ 1, 2 and 3) share great functional similarity with type I IFNs, but 
have more restricted tissue specificity. Although they engage a distinct receptor, the downsteam 
signalling pathway is the same (77). 
7.1.2 Ribavirin 
After its synthesis in 1970, the first approved use of RBV was for the treatment of respiratory 
syncytial virus infection. On account of its broad spectrum antiviral activity, it was tried as 
monotherapy, and then as a combination therapy with IFN for chronic hepatitis C, showing 
sizeable improvement in response rates. The exact mechanism by which RBV acts is not yet 
known, but a number of theories enjoy experimental support. Some of the accepted mechanisms 
are listed below (9). 
1) Being a guanosine analogue, it gets phosphorylated intracellularly, and is then 
misincorporated into nascent viral RNA resulting in premature chain termination and inhibition 
of replication. 
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2) Ribavirin monophosphate competitively inhibits inosine monophosphate dehydrogenase, 
leading to depletion of the GTP essential for viral RNA synthesis. 
3) RBV reduces the replication efficiency of the virus, thus acting as a viral mutagen and leading 
to reduced virion infectivity. 
4) It is believed to modulate the TH1/ TH2 balance towards the TH1 type response, which is 
associated with viral clearance. 
7.2 Virological response and viral kinetics 
Serial monitoring of viral load in patients on therapy is done to assess and prognosticate the 
treatment response. There are specified time points during the course of treatment at which viral 
load should be measured. The response definitions and treatment milestones are discussed below 
(66). 
Table 2.Response definitions and treatment milestones 
Treatment response or milestone Definition 
Rapid virologic response (RVR) No detectable HCV RNA in plasma at treatment wk 4 
Early virologic response (EVR) ≥2 log10 fall in HCV RNA in plasma at treatment wk 12 
Extended rapid virological 
response (eRVR) 
No detectable HCV RNA at 4 wk (rapid) and 12 wk 
(extended) of treatment 
Delayed virological response 
(DVR) 
≥2 log10 fall but  detectable HCV RNA at treatment wk 
12 and an undetectable HCV RNA at wk 24  
End of treatment response (ETR) No detectable HCV RNA in plasma at end of treatment 
(depending upon genotype and response) 
Sustained virologic response 
(SVR) 
No detectable HCV RNA in plasma at six months after 
end of treatment 
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Virological responses to IFN-α based treatments are divided into three broad groups (67). 
1) On-treatment response with SVR after treatment 
 No detectable HCV RNA in plasma at six months after end of treatment 
2) On-treatment response and relapse 
Undetectable levels of HCV RNA in the plasma of the patient while on treatment but 
detectable HCV RNA after the treatment is stopped 
3) Non-response 
(a) Null response: 
 Less than 2 log10 fall in HCV RNA levels in the plasma of the patient at 12 weeks of 
treatment.  
These patients are considered to be true non‑responders to PEG-INFα and RBV therapy. 
(b) Partial response: 
Greater than 2 log10 fall in HCV RNA levels at 12 weeks of treatment, but HCV RNA 
remains detectable throughout the entire course of treatment. 
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Figure 6.Virological responses following IFN-α based treatments for chronic hepatitis C,  
Adapted from Heim, (67)      
These different response patterns have different implications. An SVR has been found to be 
associated with a long term response and viral clearance in more than 95% of cases in several 
studies where the cases were followed up for 5 to 13 years (78,79). Additionally, marked 
histologic improvement has been seen following viral clearance. A transient response with 
relapse is seen in less than a quarter of patients on treatment. Retreatment may sometimes benefit 
such patients, but mostly needs a longer course or higher doses (80). Lastly, about a third of the 
patients show non-response to treatment. HCV RNA remains detectable throughout the course of 
the treatment and thereafter, though titres may show some decline. A number of factors have 
been related to non response and relapse, and have been discussed in detail in a separate section. 
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7.3 Treatment guidelines for PEG-INF and RBV combination therapy 
The duration of treatment required is dependent on the genotype and the response seen. WHO 
has released guidelines for care and treatment of chronic hepatitis C patients in April 2014, as 
discussed below (66). 
 
Figure 7.Duration of PEG-INF and RBV therapy for infection with HCV genotypes 1 and 4 
 
The treatment duration with PEG-INF and RBV combination may be varied depending on the 
response to treatment. If RVR is achieved and pre-treatment viral load is less than 400,000 
IU/mL, treatment duration can be reduced to 24 weeks. If viral load is detectable at 24 weeks of 
therapy, stopping the treatment is recommended. On the contrary, if the patient is showing a slow 
response with a ≥2 log drop at 12 weeks of treatment and DVR at week 24, a prolonged 
treatment for 72 weeks can be considered. 
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Figure 8.Duration of PEG-INF and RBV therapy for infection with HCV genotypes 2, 3, 5 
and 6 
 
RVR is associated with a high probability of SVR, so a short treatment for 24 weeks is sufficient. 
If the viral load shows less than 2 log drop, or is positive at 24 weeks of therapy stopping the 
treatment is recommended. On the contrary, if the patient is showing a slow response with a ≥2 
log drop at 12 weeks of treatment and DVR at week 24, a prolonged treatment for 48 weeks can 
be considered. 
7.4 Adverse effects of PEG-INF and RBV 
A major factor limiting therapy with PEG-INF and RBV is the severe adverse effects associated 
with it, which often leads to premature withdrawal from treatment. Most patients experience flu- 
like symptoms soon after the first dose, but that settles in a couple of weeks. Interferon-α 
commonly causes transient bone marrow suppression, leading to neutropenia, thrombocytopenia 
and anaemia. These haematological abnormalities may warrant dose reduction or administration 
of blood cell growth factors (81). The most difficult to manage are the neuropsychiatric side 
effects such as acute psychosis, anxiety, memory loss, depression, sleep disturbance and 
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cognitive changes. A combination of counseling, antidepressants and anxiolytic agents may be 
needed (82). Other less common adverse effects include alopecia, severe skin rash, hyper or 
hypothyroidism, disordered glucose metabolism, interstitial pneumonitis and ophthalmological 
abnormalities. Marked interaction with other drugs may be seen. RBV causes dose dependant 
haemolytic anaemia and is a known teratogen. The use of IFN and RBV is contraindicated in a 
number of conditions like transplant recipients, autoimmune hepatitis, active psychiatric illness 
and untreated hyperthyroidism and severe uncontrolled concurrent diseases like hypertension, 
diabetes, epilepsy, chronic obstructive pulmonary disease, coronary artery disease, 
haemoglobinopathies etc. 
 
 
Figure 9.The time course of side effects associated with interferon treatment 
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8. Factors affecting response to treatment 
The goal of therapy in chronic HCV infection is the attainment of SVR, which predicts 
eradication of HCV RNA and decreased complications. A number of factors are known to 
influence the response to interferon based therapies and, therefore the likelihood of an SVR. 
These factors are broadly classified as viral and host factors, and are discussed in detail below. 
8.1 Viral factors 
1) Viral genotype 
The most important viral factor that has a bearing on response to interferon based therapy is the 
genotype of the infecting virus. Though the underlying functional mechanism is unknown, there 
is an inherent difference in response to treatment among the various genotypes of HCV, which is 
the reason for the different treatment durations needed for them. Many large trials have 
attempted to study and compare the response rates in the various genotypes. The SVR rates for 
PEG-INF and RBV combination therapy have been estimated as follows. 
Table 3.Rates of SVR in different genotypes of HCV  
HCV Genotype SVR rates (PEG-INF + RBV) References 
Genotype 1                     41-52% (83–87) 
Genotype 2 and 3 65-80% (85,87–89) 
Genotype 4 50-70% (90,91) 
Genotype 5 63-67% (92–94) 
Genotype 6 62-80% (95,96) 
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2) Baseline viral load 
Pre-treatment viral load has been found to be an independent predictor of treatment response for 
all genotypes. Lower baseline viral loads (≤600,000 to 800,000 IU/mL) are associated with 
greater response rates (83,86,88,97).  
3) Viral quasispecies 
An increased degree of quasispecies heterogeneity is associated with a lower probability of SVR 
(9). It has been found that during treatment quasispecies decrease rapidly in the patients who 
attain SVR (98).  
8.2 Host factors 
1) Age 
It has been shown in large multicenter clinical trials that younger patients show better response 
rates to treatment. Fried et al.(87) in their randomised clinical trial involving 1121 patients of 
genotypes 1 to 6 found age ≤ 40 years to be significantly associated with the achievement of 
SVR (odds ratio 2.60; 95 percent confidence interval 1.72 to 3.95 and P<0.001).  In another large 
study by Shiffman et al.(89) on 1465 genotype 2 and 3 patients, age ≤ 45 years was predictive of 
SVR (odds ratio 1.50; 95% confidence interval 1.17 to 1.93 and P = 0.002). The poorer response 
in the older patients is believed to be attributable to the more extensive liver damage owing to 
the longer duration of the disease in them (83).  
2) Gender 
Female gender has been linked to a better response to treatment (9,67) while some studies have 
not been able to establish a significant association (87,89). 
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3) Ethnicity 
Ethnicity also has a significant impact on response to treatment. It has been demonstrated that 
Asians respond best to interferon based treatment, followed by Caucasians and then African 
Americans (97). The lowest response rates seen in African Americans was attributed to the 
commonness of HCV genotype 1 infection in them (83). However, this is being increasingly 
ascribed to the differential distribution of the IL28B polymorphisms in various ethnic groups 
(99,14).  
4) Body weight and BMI 
High body weight is inversely correlated with SVR. Fried et al.(87) found that body weight of 75 
kg or less was predictive of SVR (odds ratio 1.91; 95 percent confidence interval 1.27 to 2.89; 
P=0.002). Likewise Shiffman et al.(89) found a significant association with weight  ≤  80kg 
(odds ratio 1.75; 95% confidence interval 1.37 to 2.24; P<0.001).  
5) Liver fibrosis and steatosis 
 Advanced liver fibrosis or cirrhosis are major predictors of non-response,  across  all  genotypes 
(97). In a clinical trial involving 4913 patients by Jacobson et al.(85) the odds ratio for SVR in 
patients with cirrhosis compared to those without cirrhosis was 0.58 (95% CI 0.47-0.73, P 
<0.0001). Similarly steatosis also impairs the likelihood of achieving SVR (100). 
6) Diabetes mellitus 
Diabetes mellitus and insulin resistance has emerged as a cofactor in failure to achieve SVR, 
because of the higher prevalence of steatosis and advanced fibrosis in diabetics(101). 
Interestingly, successful treatment of HCV infection has shown to reduce the risk of 
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development of type 2 diabetes by attenuating insulin resistance, restoring pancreatic beta-cell 
function, and reverting glucose abnormalities in pre-diabetics (102,103).  
7) IL28B polymorphisms 
Single nucleotide polymorphisms (SNPs) refer to base-pair variations at a particular genomic 
location with a minor allele frequency of >1% within a population. Between 2009 and 2010, four 
independent genome-wide association studies across the world identified SNPs in the vicinity of 
the IL28B gene on chromosome 19 to be highly predictive of response to PEG-IFN and RBV  in 
chronic HCV infection (10–12,104). These studies included patients of different ethnicities  
(Caucasian, African American, Australian and Japanese). In the largest of these studies by Ge et 
al.(10) on 1137 patients infected with HCV genotype 1, several IL28B polymorphisms encoding 
IFN-λ3 were identified to be significantly more common in responders than in non responders, in 
patients of both European and African-American ethnicities. It was also suggested that the 
greater frequency of favourable genotypes in Europeans may be largely responsible for the better 
response rates seen in them compared to African-Americans.  
Biology of IFN- λ  
The IL29, IL28A and IL28B genes located on chromosome 19 code for IFN- λ1, IFN- λ2 and 
IFN- λ3 respectively, which constitute the IFN-λ family which is categorized as type III IFN 
(IFN-α/β/ω are classified as type I and IFN-γ as type II). The type III IFNs are functionally 
similar to type I and exert antiviral activity via the same downstream signalling pathway, as 
discussed in a previous section. However the transmembrane receptors to which these classes of 
IFNs bind are different which may result in altered kinetics of ISG expression (105).  
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IL28B SNPs 
Of the various SNPs studied, rs12979860 and rs8099917, both in the vicinity of IL28B, have 
shown the strongest association with treatment response. 
 
 
rs12979860 is located 3 kb upstream of the IL28B gene, while rs8099917 SNP is located 8 kb 
downstream. The possible genotypes at rs12979860 are C/C, C/T and T/T, while those at 
rs8099917 are T/T, T/G and G/G. The C/C genotype of rs12979860 and T/T of  rs8099917  have 
been shown to be associated with a better treatment response (10,104). The exact mechanism by 
which these polymorphisms impact treatment response is yet to be elucidated, but it has been 
found that the CC genotype is associated with lower intrahepatic ISG levels, which is linked to 
better response to IFN based treatment (106). As the two SNPs are in strong linkage 
disequilibrium, rs8099917 is believed to act by similar mechanisms (107). 
IL28B polymorphisms and spontaneous clearance of HCV infection 
Spontaneous clearance of HCV is seen in a very small number of cases, while chronicity is the 
major outcome. Thomas et al. (14) determined IL28B rs12979860 polymorphisms in large HCV 
cohorts, consisting of patients who had cleared the infection spontaneously (n = 388)  and those 
who had persistent infection (n = 620). They found that the C/C genotype was associated with 
about three fold higher clearance rates than the non C/C in patients of both European and African 
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ancestry. Similar were the findings in another homogeneous German HCV infected cohort (108). 
In their genome wide association study, Rauch et al. found rs8099917 polymorphisms to impact 
spontaneous clearance not only in HCV mono-infected but also in HCV/HIV coinfected 
individuals (104).  
IL28B polymorphisms and treatment response in HCV genotype 1 and 4 infections 
 After the genome wide association studies established the significance of these polymorphisms 
in genotype 1 infection, several studies replicated the association (109,110). Thompson et al. in 
their study on 1587 HCV genotype 1 infected patients established rs12979860 as the strongest 
pre treatment predictor of SVR (111). Significant association of the polymorphism with 
treatment response has also been found in genotype 4 infections subsequently (15,112). A meta-
analysis of 11 studies encompassing 1284 HCV 4 mono-infected patients found rs12979860 
genotype CC and rs8099917 genotype TT to be statistically significant predictors of SVR (113). 
Jia et al. in their meta-analysis of 34 papers have found these SNPs to be associated with 
response in genotypes 1 and 4, but not for 2 and 3 (107). A larger meta-analysis of 67 studies 
showed a similar result for genotypes 1 and 4 (16). 
IL28B polymorphisms and treatment response in HCV genotype 2 and 3 infections 
The association of IL28B polymorphisms with response to treatment in HCV genotype 2 and 3 
infections have remained controversial. Mangia et al. in their study involving 268 patients 
(genotype 2= 213; genotype 3= 55) found that the CC genotype was associated with SVR in 
patients who did not achieve an RVR, but not in those who did (114). In contrast, Sarrazin et al. 
studied 267 patients (genotype 2= 77, genotype 3= 190), and found an association between 
IL28B CC type and SVR in the subgroup of patients who achieved RVR. No association was 
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observed in patients who did not attain RVR (115). In two studies on genotype 3 patients 
exclusively, both rs12979860 and rs8099917 could not be associated with SVR (116,117). 
Similarly, the results of meta-analyses in this group have also been conflicting. Jia et al. (107) in 
their meta-analysis concluded that these polymorphisms did not have an association with PEG-
INF and RBV therapy in genotypes 2 and 3. Chen et al. found no association of rs12979860 with 
SVR, but showed that TT at rs8099917 SNP was predictive of a favourable response in genotype 
2 infected Asian patients (118). Another meta-analysis found an association with SVR and RVR 
in Caucasian subjects. On the contrary, the favourable IL28B genotype was found to be 
predictive of RVR, but not SVR in Asian HCV genotype 2 patients (119). However, the largest 
meta analysis by Jiménez-Sousa et al. found significant associations rs12979860 and rs8099917 
polymorphisms with treatment response in genotypes 2 and 3 infected patients, but the strength 
of association was three fold lower than that for genotypes 1 and 4 (16). It has been suggested 
that the inherently higher treatment response rates in these genotypes might attenuate the effect 
of SNPs, and this necessitates the study of larger sample sizes to find significant differences 
(16,120). 
The Indian scenario 
In 2012, Sivaprasad et al. (17) studied the distribution of genotype and allelic frequency of 
IL28B rs12979860 polymorphism in 220 healthy uninfected controls in Andhra Pradesh, India, 
and found that the frequency of CC genotype (59%) was significantly higher compared to CT 
(34.09%) and TT (6.81%). However the association of these SNPs with treatment response was 
not looked into. Thereafter two studies have attempted to find out the association of this SNP in 
HCV genotype 3 patients.  
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Gupta et al. (18) from New Delhi analysed the rs12979860 SNP in 356 patients infected with 
HCV genotype 3 and found the CC genotype to be an independent strong predictor of RVR and 
SVR. The rs12979860 genotype CC/ CT/TT distribution was 58.3%, 34.5%, and 7.2% 
respectively. SVR was seen in 250 (70.2%) patients. The non-CC genotypes were found in 
67.6% in non-responders, compared to a much lower 38.9% in responders (P<0.001).  360 
matched uninfected individuals served as healthy controls, in whom the genotype CC/CT/TT 
distribution was found 60.6%, 35.2%, and 4.2% respectively.  
In a study by Firdaus et al. (19), 400 HCV seropositive patients from Eastern and North Eastern 
India were genotyped for rs12979860 and rs 8099917 polymorphisms. Out of the total, 293 
(73.25%) were positive for HCV RNA (genotype 3=193, genotype 1=94 and genotype 6=6). 
IL28 B genotyping was done for all 400 cases. The frequency of CC/ CT/TT genotype at 
rs12979860 was 70.75%, 24% and 5.25%, while that of TT/TG/GG genotype at rs8099917 was 
77.50%, 15% and 7.50 respectively. In the control group including 100 healthy individuals, the 
distribution at locus rs12979860 was 73%, 23% and 4% for CC/ CT/TT.  At rs8099917 the 
favourable genotype TT was found in 70% individuals, followed by TG in 30%. There were no 
GG alleles in this group. 
Among the 293 viral RNA positive individuals, 83 genotype 3 infected individuals were treated 
with PEG-INF and RBV. SVR was achieved in 46 out of 83 individuals (55.42%) while RVR in 
26 individuals (31.3%).  Genotypes CC at rs 12979860 and TT at rs8099917 were found to be 
strongly associated with SVR. 
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This study aims to determine the frequency and distribution of IL28B gene polymorphisms in 
patients with chronic HCV infection harbouring genotype 1 in addition to 3, and to study the 
association of these SNPs with response to IFN based treatment.  
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MATERIALS AND METHODS 
Study Design 
This is an observational study conducted in the Department of Clinical Virology, Christian 
Medical College, Vellore. Patients infected with HCV on treatment with Interferon (standard / 
pegylated) and RBV were recruited from the Liver Clinic and in-patient wards of the Department 
of Hepatology. 
 
Ethics approval: 
The approval for the study was obtained from the Institutional Review Board, CMC, Vellore 
(IRB Min No: 8202 dated 13.02.13).  
 
Study duration:  
The study was conducted over a period of 17 months from April 2013 to August 2014. 
 
Study samples: 
The study subjects comprised of individuals attending the Liver Clinic of Christian Medical 
College, Vellore, on treatment for HCV infection.  These subjects were referred to the 
Department of Clinical Virology for routine hepatitis C viral load testing and /or HCV 
genotyping. Written informed consent was obtained from the patient at the time of blood 
collection for routine testing. 
Inclusion Criteria: 
1. ≥18 years of age 
2. Patients with HCV genotype 1, 3 and 4 infection  
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3. On therapy with Interferon (standard or pegylated) and RBV 
Exclusion Criteria: 
1. Immunosuppressed patients 
2. Hepatitis B or HIV co-infection 
3. Patients on dialysis 
4. Pregnancy 
5. Tuberculosis 
 
Data sources: 
Relevant information about the patient, like age, sex, address, weight, height, diabetic status, 
ALT levels, was obtained from clinical records. Testing of the study samples was done in the 
Department of Clinical Virology. 
 
Study algorithm 
Diagrammatic representation of the study algorithm is shown below. 
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Patient referred to Virology department for HCV viral load 
testing/ HCV genotyping as part of routine management 
Informed consent taken 
Patient proforma filled 
8ml blood collected in EDTA tube and centrifuged at 2500 rpm for 10 mins 
Plasma 
Buffy coat stored at -80°C 
-70°C 
HCV PCR / genotyping as a part of 
routine management 
(as a part of study when not ordered 
by the clinician) 
HCV Genotype 1, 3, 4 
Patient excluded from 
study 
Genomic DNA extraction 
PCR-RFLP 
PCR-Sequencing (on a subset of samples) 
  
 
Detection of IL 28B polymorphisms 
 
N
o 
Yes 
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1. Processing of study samples 
8 to 10 mL of blood was collected by venipuncture in vacutainer tubes containing dipotassium 
ethylene diamine tetra acetate (K2EDTA) (BD Biosciences). The tube was centrifuged at 2500 
rpm for 10 minutes and the supernatant plasma was transferred out with a pipette. This was 
stored at -60°C HCV viral load testing and/or genotyping as a part of routine management. Then 
the buffy coat layer was carefully pipetted out was and was added to an aliquot of cell freezing 
solution to make up a volume of 200 µl. This was stored at -60°C until testing. 
Preparation of the cell freezing solution  
The glycerol cell freezing solution was prepared as per the guidelines by Austin et al. (121)  
Requirements 
Reagent Amount per 100 ml 
Citric acid, sodium salt 1.47 gm 
Sodium phosphate, monobasic monohydrate 0.276 gm 
Sodium phosphate, dibasic anhydrous 0.284 gm 
99% glycerol 40.00 ml 
 
1. The salts were weighed and added to 40 ml glycerol. 
2. The volume of the solution was adjusted to slightly less than 100 ml using sterile distilled 
water. 
3. Concentrated sodium hydroxide was added to bring the pH to 7.4. 
4. The final volume was brought to 100 ml using sterile distilled water. 
5. The solution was filtered, aliquoted into micro centrifuge tubes, 1ml each, and stored at 4°C. 
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2. DNA extraction from the buffy coat 
A. Materials required 
Buffy coat saved in cell freezing solution (200 µl) 
QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, Germany) containing: 
Proteinase K 
Lysis buffer AL 
Wash buffer 1 AW1 
Wash buffer 2 AW2 
Elution buffer AE 
QIAamp Mini Spin Columns 
Collection Tubes (2 ml)  
Ethanol 
Nuclease free water 
Dry bath (temperature to be set at 56°C) 
B. Procedure 
DNA extraction was performed in the „PCR dirty‟ room as per manufacturer‟s instructions. 
1. The samples were equilibrated to room temperature and dry bath was set to heat to 56°C. 
2.  Proteinase stock solution was prepared by adding 1.2 ml of proteinase solvent into the vial 
containing lyophilized protease. The solution was stored at 2-8°C. 
3. 20 µl of Proteinase K was pipetted into a 1.7 ml micro centrifuge tube, to which 200 µl of the 
thawed sample was added. 
4. 200 µl of AL was added to the tube and mixed well by pulse vortexing for 15 seconds. 
5. The tube containing the above mixture was incubated in a dry bath at 56°C for 10 minutes. 
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6. The tube was then centrifuged briefly to remove moisture from the inside of the lid. 
7. 200µl of 100% ethanol was added to the sample and mixed well by pulse-vortexing for 15 
second and briefly spun down. 
8. The entire content (620 µl) was transferred to the spin column (silica-gel membrane) and 
centrifuged at 8000rpm for one minute.  
9. The filtrate along with the collection tube was discarded and the mini spin column was placed 
on a fresh collection tube. 
10. 500µl of AW1was added to the mini spin column and centrifuged at 8000rpm for one minute. 
11. The collection tube with the filtrate was discarded and the mini spin column was placed on a 
fresh collection tube. 
12. 500µl of AW 2 was added to the spin column and this was centrifuged at 14,000 rpm for 3 
minutes. 
13. The collection tube with the filtrate was discarded and the mini spin column was placed on a 
fresh collection tube and centrifuged at 14,000 rpm for 1 minute.  
14. The collection tube was discarded and the spin column was placed in a 1.5 ml micro centrifuge 
tube. 100µl of elution buffer AE was added to the spin column and incubated at room temperature 
for one minute, and then centrifuged at 8000rpm for one minute. 
15. The DNA extract was stored in aliquots at -20°C. 
3. Genomic DNA quantification 
The extracted DNA was quantified spectrophotometrically using Take3, Gen5
TM
, Biotek. 2 µl of 
the extracted DNA was loaded on the Take3 microplate and readings were taken using the Gen5
TM
 
software. Both the concentration and purity of DNA was determined. 
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4. IL28B genotyping by polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) 
Principle: 
Polymerase chain reaction amplifies a specific target region of the template DNA strand. RFLP is 
based on the digestion of the PCR product by restriction endonucleases at specific sites depending 
upon nucleotide variations at the site of polymorphism. This produces DNA fragments of precise 
lengths giving discrete electrophoretic patterns based upon their sizes. Using suitable primers and 
cycling conditions the two target sites rs12979860 and rs8099917 were amplified separately. 
Digestion of the PCR products with restriction enzymes was carried out and the two 
polymorphisms were detected depending upon the electrophoretic patterns produced. 
4.1. PCR 
4.1.1. Primers 
Primers for the amplification of rs12979860 and rs8099917 were the same as that used by Sharafi 
et al.(122) 
rs12979860  
Forward primer 
 
5‟ GCGGAAGGAGCAGTTGCGCT 3‟ 
Reverse primer 5‟ GGGGCTTTGCTGGGGGAGTG 3‟ 
rs8099917 
Forward primer 
 
5‟ CCCACTTCTGGAACAAATCGTCCC 3‟ 
Reverse primer 5‟ TCTCCTCCCCAAGTCAGGCAACC 3‟ 
The lyophilised primers were reconstituted using Tris EDTA (TE) buffer. 
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4.1.2. Master mix  
The concentrations of the different components of the PCR mix for one reaction are given below: 
Reagents Volume per reaction (µl) 
HotStar Taq master mix (Qiagen, Hilden, 
Germany) 
12.5 
Forward primer 1 (10 pmol/ µl) 
Reverse primer 1 (10 pmol/ µl) 
Nuclease free water 5.5 to 9.5 
DNA extract (100 to 300 ng) 1 to 5 
Total volume 25 
 
4.1.3. Procedure for amplification 
1. The master mix was prepared for the appropriate number of reactions with the above template. 
The master mix was prepared in the clean room or „DNA-free‟ room. Separate master mixes were 
prepared for the two reactions.   
2. Appropriate number of 0.5ml PCR tubes were labeled appropriately, and the master mix was 
distributed in them. 
3. DNA extracts were removed from the storage area, brought to room temperature and spun 
briefly in a microcentrifuge. 
4. 1 to 5 µl of DNA was added, depending upon the concentration. The final volume was 25 µl. 
Addition of DNA was done in the „dirty room‟. 
5. Nuclease free water was used as negative control after every three samples. 
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6. Amplification reactions were carried out in Veriti 
TM
 Thermal Cycler (Applied Biosystem, 
Foster City, California, USA) 
7. The cycling conditions were:  
 
rs12979860 
Initial denaturation:  95
o
C for 15 minutes 
Denaturation:  95
o
C, 30 sec    
Annealing:  60
o
C, 30 sec   
Extension:  72°C for 45 min 
Final extension:  72°C for 7 min 
 
rs8099917 
Initial denaturation:  95
o
C for 15 minutes 
Denaturation:  95
o
C, 30 sec    
Annealing:  56
o
C, 30 sec   
Extension:  72°C for 45 min 
Final extension:  72°C for 7 min 
 
8. The length of the expected amplification products were  
rs12979860: 241 base pairs                                   rs8099917: 552 base pairs 
 
 
 
X 40 Cycles 
X 40 Cycles 
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4.1.5. Post amplification DNA detection by Gel Electrophoresis: 
1. Five microlitres of each amplicon was mixed with 1 µL of 6X loading dye bromophenol 
blue. 
2. The amplified products were then subjected to electrophoresis in freshly prepared 2% 
agarose gel containing 0.5 µg/ml ethidium bromide. 
3. Test samples and negative control were loaded in appropriate wells. Molecular ladder (DNA 
Marker-A, Bio Basic Inc.Canada) used was 25-500 bp long. 
4. The electrophoresis was done at 120 volts for 35 minutes. 
5. The gel was visualized by ultraviolet radiation using Quantity one® (version 4.6.2) software in 
the gel documentation system (BioRad, Hercules, California, USA). 
4.2. Restriction Fragment Length Polymorphism 
For RFLP analysis, digestion of the amplicons was carried out using restriction endonucleases 
BstUI (New England Biolabs, UK) for rs12979860 and BsrDI (New England Biolabs, UK) for 
rs8099917.  
The reaction volumes were as follows.  
                rs12979860 analysis                                                 rs8099917 analysis 
Reagent 
Volume per reaction 
(µl) 
Reagent 
Volume per reaction 
(µl) 
BstUI 2 BsrDI 2 
Buffer 2 Buffer 2 
Nuclease free water 8 Nuclease free water 8 
Amplified product 8 Amplified product 8 
Total volume 20 Total volume 20 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
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The reactions for rs12979860 were incubated at 60°C for 15 minutes, and those for rs8099917 at 
65°C for mins Veriti 
TM
 Thermal Cycler (Applied Biosystem, Foster City, California, USA).  
Gel Documentation following RFLP 
Ten microlitres of each amplicon was mixed with 2 µL of 6X loading dye bromophenol blue and 
then subjected to electrophoresis in freshly prepared 3% agarose gel containing 0.5 µg/ml 
ethidium bromide. Molecular ladder (DNA Marker-A, Bio Basic Inc.Canada) used was 25-500 
bp long. The gel was visualized by ultraviolet radiation using Quantity one® (version 4.6.2) 
software in the gel documentation system (BioRad, Hercules, California, USA). 
Interpretation of electrophoretic patterns after RFLP 
rs12979860  
Bands obtained Genotype 
196, 45 base pairs CC 
241, 196, 45 base pairs CT 
241 base pairs 
 
TT 
rs8099917  
Bands obtained Genotype  
552 base pairs TT 
552, 322,230 base pairs GT 
322, 230 base pairs GG 
 
5. IL28B genotyping by polymerase chain reaction-sequencing 
A representative set of samples (5 each for rs12979860 and rs8099917) were bidirectionally 
sequenced by Sanger sequencing for verification of RFLP results. 
 
1 2 3 4 5 6 7 8 9 10 11 
10 
12 13 14
  14 
15
  14 
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Principle: 
This is a „chain termination‟ method of DNA sequencing to determine the precise order of 
nucleotides in a segment of DNA. After amplification of the target region, the products are purified 
in order to remove extra dNTPs and primers (Pre-cycle sequencing clean-up). This is followed by 
PCR to synthesize single stranded DNA templates. The reaction mix for the PCR contains, along 
with the four deoxynucleotide triphosphate (dNTPs), limited amounts of different dideoxy 
nucleoside triphosphate (ddNTPs).  These ddNTPs get incorporated into the chain by DNA 
polymerase, as efficiently as dNTPs. However, as they lack the 3'-OH group required for 
attachment of the next nucleotide, their incorporation brings about chain termination. This process 
generates fragments randomly that differ in length by one base pair. In automated cycle sequencing 
using dye terminator chemistry, the ddNTPs are tagged with different fluorescent dyes, each 
emitting light at a unique wavelength when excited by a laser. As the products are subjected to 
capillary electrophoresis in a genetic analyzer, a laser excites the fluorescent dye labels at the 3‟ 
ends of the ddNTPs, and depending upon the unique wavelength emitted, the nucleotide is 
identified as adenine (A), cytosine (C), guanine (G) or thymine (T). The emitted fluorescence is 
recorded by a camera and a software converts the data to a colour coded electropherogram, in 
which blue represents C, green represents A, black represents G and red represents T. 
5.1. DNA amplification by PCR 
1. The primers used were the same as those for PCR-RFLP, except the reverse primer for 
rs12979860, which was as follows: 5‟ GTGCCTTCACGCTCCGAGCA 3‟ 
2. The master mix preparation was done in the same manner as PCR-RFLP. The cycling conditions 
were also the same.  
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3. Amplification of rs12979860 produced a 746 base pair product while rs8099917 amplification 
produced a 552 base pair product.  
4. Electrophoresis of the amplified products was done on 2% agarose gel.  
5. The gel was visualized by ultraviolet radiation using Quantity one® (version 4.6.2) software 
in the gel documentation system (BioRad, Hercules, California, USA). 
5.2. Pre-cycle sequencing clean-up 
1. After gel documentation to ensure optimal amplification, 80 µl of nuclease free water was 
added to the amplicon to make the volume 100 µl. 
2. The diluted product was transferred to the Multiscreen HTS PCR plate (Millipore, Billerica, 
USA). 
3. The pre-sequencing plate was placed on the Millipore vacuum manifold and vacuum pressure 
was applied until the well was completely dry. 
4. The above step was repeated with 100 µl of nuclease free water. 
5. After the wells dried completely, 10 µl of nuclease free water was added and mixed in titer 
plate shaker (Barnstead International, Dubuque, USA) for 2 minutes at 7000 rpm. 
6. Thus 10 µl of purified DNA was eluted, and transferred to PCR tubes. 
5.3. Sequencing PCR 
1. Sequencing reactions were carried out for the forward and reverse strands using ABI Prism 
BigDye® terminator v3.1 cycle sequencing reagents. 
2. The reaction volumes were as follows.      
1 2 3 4 5 6 7 8 9 10 11 12
  12 
13 14 
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Reagent Volume per reaction (µl) 
Ready reaction (RR) mix 0.5 
Sequencing buffer 1.75 
Primer (Forward/Reverse) 2 (1 pmol/µl) 
Purified PCR product 1 
Nuclease free water 4.75 
Total volume 10 
 
3. The cycling conditions were 
   96°C for 15 seconds 
   50°C for 20 seconds 
   60°C for 4 minutes 
 
5.4. Post cycle sequencing clean-up 
1. 30 µl of injection solution was added to the sequence reaction samples. 
2. The diluted reactions were transferred onto Montage SEQ96 filtration plates (Millipore 
Billerica, USA). 
3. The plate was placed on the Millipore vacuum manifold and vacuum was applied until the 
wells were completely dry. 
4. 40 µl of injection solution was added to the wells and the step was repeated.  
5. After the wells dried completely 30 µl of injection solution was added and mixed in titer plate 
shaker (Barnstead International, Dubuque, USA) for 2 minutes. 
6. 30 µl of the resuspended DNA thus obtained was transferred to genetic analyzer sample tubes 
and sealed with septa. 
 
25 cycles 
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5.5. DNA sequencing and sequence analysis 
ABI PRISM 310 genetic analyzer (Applied Biosystems, Foster City, California, USA) was used 
for the DNA sequencing. Bidirectional sequences were obtained for both the targets and 
analyzed using BioEdit sequence alignment editor. Reference sequences for rs12979860 and 
rs8099917 were downloaded from NCBI SNP database. The obtained sequences were aligned 
with the reference sequence and the polymorphisms were detected. 
6. HCV Genotyping 
Genotyping of HCV was done as a part of the study for cases where the test was not ordered as a 
part of the routine management. This is based upon sequencing of the NS5B region of the HCV 
genome (123). The procedure involves conversion of RNA into c DNA (reverse transcription), 
and subsequent amplification of the c DNA. A nested PCR involving two consecutive PCRs is 
performed. 
 The steps for the procedure are as follows 
6.1. Viral RNA Extraction from plasma 
Materials required: 
 Plasma sample (either freshly separated or stored at -60°C) 
            QIAamp® Viral RNA Mini kit containing 
  Buffer AVL 
Buffer AW1 
  Buffer AW2 
  Buffer AVE  
  Carrier RNA 
  Spin columns 
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  Collection tubes (2ml) 
 100% ethanol 
 Nuclease free water (to serve as negative control) 
Procedure: 
The method as recommended by the manufacturers was followed for the extraction process.  
1. Before starting the extraction process carrier RNA solution was prepared by adding 310 µl 
Buffer AVE to the tube containing 310 µg lyophilized carrier RNA. This was thoroughly 
dissolved, divided into conveniently sized aliquots, and stored at –20°C. 
2. For each batch of extraction Buffer AVL and carrier RNA- Buffer AVE  mix was freshly  
prepared, in appropriate proportions (for one sample Buffer AVL = 0.56,  carrier RNA- Buffer 
AVE=5.6). 
3. The tubes were labelled appropriately and plasma samples were equilibrated to room 
temperature. 
4. 560 µl of prepared Buffer AVL containing carrier RNA was pipetted into a 1.5 ml 
microcentrifuge tube. 
5. 140 µl of plasma sample was added to the tube and mixed by pulse-vortexing for 15 s. 
6. The mixture was incubated at room temperature (15–25°C) for 10 min and then  spun briefly 
to remove moisture from the inside of the lid. 
7. 560 µl of ethanol was added to the sample, and pulse-vortexed for proper mixing followed by 
brief centrifugation.  
8. 630 µl of this solution was transferred to the spin column (silica-gel membrane) and 
centrifuged at 8000rpm for one minute. 
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9. The filtrate along with the collection tube was discarded and the mini spin column was placed 
on a fresh collection tube. 
10. Remaining 630 µl of the solution in the microcentrifuge was transferred to the spin column, 
and centrifuged at 8000rpm for one minute. The collection tube with the filtrate was discarded and 
the mini spin column was placed on a fresh collection tube. 
12. 500µl of AW 1 was added to the spin column and this was centrifuged at 8000rpm for one 
minute, and the filtrate along with the collection was discarded and a fresh tube used. 
13. 500µl of AW 2 was then added and centrifuged 14,000 rpm for 3 minutes. The spin column 
was placed in a clean 1.5 ml microcentrifuge tube and the collection tube containing the filtrate 
was discarded. 
14. 60 µl of Buffer AVE was added to the microcentrifuge tube and after incubation at room 
temperature for 1 min it was centrifuged at 8000 rpm for 1 min. 
15. The spin column was discarded and viral RNA was eluted. 
6.2. First round PCR 
This was done using Titanium One-Step RT-PCR Kit (Clonetech laboratories, Takara Bio Inc, 
Japan).  
The primer sequences were as follows: 
P1203                             5‟ GGGTTCTCGTATGATACCCGCTGCTTTGACTC 3‟ 
P1204       5‟ GGAGGGGCGGAATACCTGGTCATAGCCTCCGTGAA 3‟ 
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The master mix was prepared as follows. 
Reagent Volume per reaction (µl) 
10X One Step Buffer 5.0 
50X dNTP mix 1.0 
Recombinant RNAase inhibitor 0.5 
Thermostabilizer 25.0 
GC melt 10.0 
50X Titanium taq polymerase 1.0 
Oligo dt primer 1.0 
P1203 (50 pmol/ µl) 0.9 
P1204 (50 pmol/ µl) 0.9 
Total 45.3 
Appropriate amount of the master mix was prepared depending upon the number of samples, and 
was divided into PCR tubes. Nuclease free water was used as a negative control after each 
sample. 5 µl of the extracted RNA was added to the tube and was taken for amplification using 
Veriti TM Thermal Cycler (Applied Biosystem, Foster City, California, USA). The cycling 
conditions used were 
             50 °C for 60 minutes 
             94°C for 5 minutes 
    94°C for 30 seconds 
    65°C for 30 seconds 
    68°C for 1 minute 
    68°C for 2 minutes   
35 cycles 
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After amplification, the products were subjected to electrophoresis on a 2% agarose gel. 
The amplified products were taken to the second round PCR. 
6.3. Second round PCR 
Primers used were P1204 (as in first round) and NS5B internal primer. 
 (5‟ TGATACCCGCTGCTTTGACTCNACNGTCAC 3‟) 
The master mix was prepared as follows: 
Reagent Volume per reaction (µl) 
10 X PCR buffer 5.0 
dNTPs (100mM) 0.4 
P1204 (50 pmol/ µl) 0.4 
NS5B primer (50 pmol/ µl) 0.4 
Taq polymerase 0.2 
Nuclease free water 38.6 
Total 45.0 
 
The master mix was distributed into required number of tubes. 5 µl of the amplified product from 
the first round PCR was added to the reaction. The samples were amplified using Veriti TM 
Thermal Cycler (Applied Biosystem, Foster City, California, USA). The cycling conditions used 
were 
  94°C for 3 minutes 
  94°C for 30 seconds 
  54°C for 40 seconds 
  72°C for 30 seconds 
  72°C for 3 minutes 
40 cycles 
1 2 3 4 5 6 
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Gel documentation for the second round products was done to verify the adequacy of 
amplification. 
6.4 Sequencing and analysis 
The second round products were subjected to pre-cycle sequencing clean up, sequencing PCR 
and post-cycle sequencing clean up, and then loaded onto the auto sampler tray of  ABI PRISM 
310 genetic analyzer (Applied Biosystems, Foster City, California, USA)  (same procedure as 
described above for IL28 sequencing). 
Forward and reverse sequences were obtained from the sequencer, and were aligned together 
using BioEdit software to get a consensus nucleotide sequence. The obtained sequence was 
subjected to BLAST using online software HCV BLAST (hcv.lanl.gov). Depending upon the 
homology found, the genotype of HCV was identified. The sample sequence was then included 
in a phylogenetic tree that has representative genotypes identified in this centre. 
 
Statistical analysis 
Continuous variables were reported as mean ± standard deviation or median. Categorical 
variables were expressed as frequencies (%). The difference in the distribution of variables was 
checked using Chi square/Fishers exact test as appropriate. A p value ≤ 0.05 was used as the 
criterion for statistical significance. All data generated in the study were analyzed using the 
SPSS software - version 16.0. 
 
 
 
 
1 2 3 4 5 6 
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RESULTS 
1. Demographic profile 
A total of 57 patients were included in the study. Majority of the patients were from Bangladesh 
(14/57, 24.6%) followed by Tamil Nadu (12/57, 21.1%), Jharkhand (9/57, 15.8%) and West 
Bengal (7/57, 12.3%) The remaining patients were from other Indian states and Nepal as shown 
in table below. 
Table 4.Region wise distribution of study patients 
Region Number of cases Percentage (%) 
Bangladesh 14 24.6 
Tamilnadu 12 21.1 
Jharkhand 9 15.8 
West Bengal 7 12.3 
Andhra Pradesh 3 5.3 
Bihar 3 5.3 
Nepal 3 5.3 
Tripura 2 3.5 
Uttar Pradesh 1 1.8 
Manipur 1 1.8 
Kerala 1 1.8 
Karnataka 1 1.8 
Total 57 100 
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Baseline characteristics 
The number of male patients (n=38) was double the females (n=19). The ages of the patients 
ranged from 24-64 years, median age being 47 years. The median weight was 62 kg and median 
BMI was 25. Baseline ALT levels varied from 10 to 271 U/ml, median being 70 U/ml. The 
distribution of baseline ALT levels (3 × upper limit of normal) was not different in patients with 
low vs. high viral loads (≤600,000 vs. >600,000 IU/ml). 
 
2. Distribution of HCV genotypes 
Of the 57 patients, 12 (21%) were infected with HCV genotype 1, 43 (75%) with genotype 3 and 
2 (4%) with genotype 4.  
 
 
 
Figure 10.Distribution of HCV genotypes in the cases 
 
 
21%
75%
4%
genotype 1
genotype 3
genotype 4
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3. IL28B genotyping analysis 
Host genotyping was done on 57 patients to determine the polymorphisms at loci rs12979860 
and rs8099917 using PCR-RFLP as described previously. The polymorphisms were identified 
based on the lengths of the bands obtained on digestion of the amplification products. 
 
 
 
 
 
 
 
                          Figure 11.Documentation under UV light following RFLP 
 
A subset of the samples were bidirectionally sequenced for verification of RFLP results. The 
figures below depict electropherograms representing the possible genotypes of the two 
polymorphisms. 
Lane 1: ladder (25 to 500 bp) 
Lanes 2 to 8: rs12979860 
Lane 2, 8: CC    Lanes 3, 6, 7: CT      Lane 4: TT 
Lanes 9 to 15: rs8099917 
Lane 9,15: TT   Lane 10,13,14: GT   Lane 11:GG  
Lanes 5 and 12: Negative control  
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Figure 12.Chromatogram showing sequence of rs12979860 (C/T) of IL28B gene. 
Lanes 1–3 show CC, CT, and TT host genotypes in that order 
 
 
Figure 13.Chromatogram showing sequence of rs8099917 (T/G) of IL28B gene. 
Lanes 1–3 show TT, GT, and GG host genotypes in that order 
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4. Frequency distribution of IL28B polymorphisms in the cases  
The frequency of CC genotype at rs1297960 was found to be 59.65 % (34 out of 57 individuals), 
compared to CT at 33.33 % (19 out of 57). Genotype TT was found in 7.02 % cases (4 out of 
57).  
 
Figure 14.Frequency distribution of rs1297960 polymorphism in cases 
 
On analysis of host genotype at rs8099917 it was found that TT was the commonest, present in 
71.93% individuals (41 out of 57), followed by GT in 22.81% cases (13 out of 57) and then GG, 
in 5.26% individuals (3 out of 57). 
 
Figure 15.Frequency distribution of rs8099917 polymorphism in cases 
60%
33%
7%
CC
CT
TT
72%
23%
5%
TT
GT
GG
84 
 
Frequency distribution of IL28B polymorphisms in HCV genotype 1, 3 and 4 infected 
patients 
The distribution of the various genotypes of the two polymorphisms were analysed separately in 
HCV genotype 1, 3 and 4 infected patients, as is depicted in the figures below. 
 
Figure 16.Frequency distribution of rs1297960 polymorphism in HCV genotype 1, 3 and 4 
infected patients. 
 
 
Figure 17.Frequency distribution of rs8099917 polymorphism in HCV genotype 1, 3 and 4 
infected patients 
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5. Follow up of the study patients 
The viral load in the patients were monitored at 4 weeks (RVR), 12 weeks (EVR), 24/48 weeks 
depending upon the genotype (ETR) and six months after end of treatment (Sustained viral 
response, SVR). Of the 57 recruited patients, 34 completed follow up till measurement of SVR 
during the course of the study (genotype 1=7, genotype 3=26 and genotype 4=1). The remaining 
23 cases were at different time points of follow up. The RVR, EVR, ETR and SVR rates were 
calculated for both genotypes 1 and 3, and are depicted in the figure below. 
 
Figure 18.Virological response at different time points in genotype 1 and 3 infected patients 
RVR Rapid virological response, EVR Early virological response, ETR End of treatment 
response, SVR Sustained virological response 
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Response was defined by achieving sustained lack of viraemia six months after completion of 
treatment, ie, SVR.  Of the 34 patients who had completed follow up till the time point of SVR 
during the course of this study, 19 achieved SVR while 15 did not, and included both non- 
responders and relapsers. Both non-responders and relapsers have been grouped together and 
referred to as non-responders in the analysis.  
The overall response rate was 55.9%. 4 out of 7 genotype 1 infected patients were responders 
(response rate = 57.1%). Similarly, 14 out of 26 genotype 3 infected patients were responders 
(response rate = 53.8%), showing no difference (P value =1.0).  
 
 
Figure 19.Rates of response (n=34) 
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Figure 20.Rates of response in HCV genotypes 1 and 3 infected patients 
 
Viral load at the various treatment milestones were plotted separately for non-responders (figure 
21) and responders (figure 23). Pre-treatment viral loads varied from 7.2x10
3
  to 7x10
6 
IU/ml, 
median being 3.8x10
5
 IU/ml.  Most of the treatment failure cases showed undetectable viral 
loads when sampled at the time point of EVR and ETR. This was then followed by bouncing 
back of HCV RNA (virological breakthrough) after cessation of therapy. Contrastingly, none of 
the treatment responders showed detectable viral load at any point of time (figure 22).  
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Figure 21A.Viral load monitoring at various time points in treatment non-responders 
(n=15) 
**
Viral load values at time points of RVR and EVR have been plotted again below, in 
order to depict values at an appropriate scale. 
 
 
Figure21B.Viral load monitoring at time points of RVR and EVR in treatment non-
responders (n=15) 
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Figure 22.Viral load monitoring at various time points in treatment responders (n=19) 
 
 All patients had undetectable viral load at all time points they were sampled, thus yielding flat 
lines in graph.  
 
 
Pre-treatment RVR EVR ETR SVR
V
ir
al
 lo
ad
 (
IU
/m
l)
Series 1
Series 2
Series 3
Series 4
Series 5
Series 6
Series 7
Series 8
Series 9
Series 10
Series 11
Series 12
Series 13
Series 14
Series 15
Series 16
Series 17
Series 18
Series 19
90 
 
6. IL28B frequency distribution in responders and non-responders 
Distribution of rs12979860 genotypes 
The frequency distribution of rs12979860 CC/CT/TT genotypes in responders (n=19) was 
84.2%, 10.5% and 5.3% respectively. On the other hand the distribution in non responders 
(n=15) was 40%, 53.33% and 6.66% for respectively. A comparative analysis of the 
distribution of these genotypes in responders and non-responders has been depicted in the 
figure below. 
 
Figure23. Frequency distribution of rs12979860 genotypes in responders and non-
responders 
 
To analyse the impact of the „C‟ allele on treatment response, genotypes CT and TT were 
grouped together as non-CC. The distribution of CC vs. non-CC was compared in responders 
and non-responders. The non-CC genotypes were found to be significantly higher in non-
responders (60%) compared to responders (15.8%), with a p value of 0.012, as is depicted in 
the figure below.  
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Figure 24.Distribution of the rs12979860 CC and non-CC genotypes in responders and 
non-responders 
 
Distribution of rs8099917 genotypes 
A similar analysis was done for rs8099917 polymorphism. The frequency distribution of 
rs8099917 TT/GT/GG genotypes in responders (n=19) was 84.2%, 10.5% and 5.3% 
respectively. The distribution in non responders (n=15) was 53.33%, 40%, and 6.66% for 
respectively. The same has been represented in the following figure. 
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Figure 25.Frequency distribution of rs8099917 genotypes in responders and non-
responders 
 
GT and GG were grouped together as non-TT. Non-TT genotypes were higher in non-
responders (46.67%) compared to responders (15.80%), although the difference was not 
significant (p value= 0.068), but showed a trend (figure 26). 
 
Figure 26.Distribution of rs8099917 TT and non-TT genotypes in responders and non-
responders 
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7. Analysis of the effect of other variables on response to treatment 
Other variables were analyzed for their effects on SVR. Of them, RVR was the only factor 
found to be a determinant of SVR. 
 A. Age  
When study participants ≤40 years vs. >40 years of age were compared for the response to 
anti-viral therapy, there was no difference between the two age groups (p value=0.426)  
 
Figure 27.Distribution of age (≤40 years vs. >40 years) in responders and non 
responders 
 
B. Gender  
Association of the gender of the study participants with treatment response was analyzed. 
However, no difference was found between males and females (p value=0.128) (figure 28) 
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Figure 28.Distribution of gender in responders and non-responders 
 
C. Body mass index  
Patients were grouped into two categories based on their BMI (≤ 25 vs. >25). However, a 
lower BMI was not found to be associated with SVR (figure 29). 
 
Figure 29.Distribution of body mass index in responders and non-responders 
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D. Rapid viral response (RVR) 
RVR refers to undetectable viral load at 4 weeks of initiation of interferon based therapy. Of 
the 34 patients analysed, 14 had a viral load measurement at the time point of RVR. Of the 14 
patients tested, 4 had detectable viral load, ie, did not attain RVR. All of these 4 patients 
turned not to be non-responders when followed up till the time point of SVR. On the other 
hand, of the 10 patients who showed undetectable HCV RNA levels at week 4 (RVR 
attained), 9 attained SVR, while 1 did not. Attainment of RVR was found to be a significant 
factor associated with response to treatment (P value=0.005). 
 
 
Figure 30.Distribution of RVR attained vs. not attained in responders and non-
responders (RVR Rapid viral response) 
 
E. Pre-treatment viral load 
Viral load before initiation of treatment was classified as low and high (≤600,000 vs. 
>600,000 IU/ml) and was analysed for its impact on response. There was no difference in the 
distribution of viral loads in responders and non-responders (P value=0.710). 
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Figure 31.Distribution of pre-treatment viral load (≤600,000 vs. >600,000) in responders 
and non-responders 
 
F. Treatment modality  
The study cases were on therapy with either PEG-IFN or standard interferon (IFN), in 
combination with RBV.  Whether the treatment modality had a bearing on virological 
response was looked at. However, no difference was found between the two groups (P 
value=0.217).  
 
Figure 32.Distribution of treatment modality (PEG-INF vs. IFN) in responders and non-
responders 
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G. Diabetes  
When study participants were grouped as diabetics and non-diabetics and compared for the 
response rates, no difference was found in the two groups  
 
Figure 33.Distribution of diabetics in responders and non-responders 
 
H. Baseline alanine transaminase (ALT) levels 
The distribution of pre-treatment ALT levels ≤105 U/ml vs. >105 U/ml (3 × upper limit of 
normal) was compared in responders and non-responders. The difference was not statistically 
significant (p value=0.08), though a trend was observed. 
 
Figure 34.Distribution of ALT levels in responders and non responders 
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A multivariate analysis was performed for all the variables. However, none of them figured 
out to be significant in the analysis.  
 
8. Association of the IL28B polymorphisms with RVR 
(a) rs 12979860 polymorphism 
The distribution of rs 12979860 CC/CT/TT genotypes was studied in individuals who 
attained RVR and those who did not (figure 35).  
The non-CC genotypes were found be much higher in those who did not attain RVR (78%), 
in comparison to those who did (27%). The difference was statistically significant (P 
value=0.017), showing that rs12979860 CC genotype was a predictor for RVR (figure 36). 
(b) rs8099917 polymorphism 
Frequency distribution of rs8099917 TT/GT/GG genotypes was studied in individuals who 
attained RVR and those who did not. (figure 37) 
The non TT genotypes were found in 18% of the individuals who attained RVR and in 56% 
of individuals who did not attain RVR.  However, the difference was not statistically 
significant, but showed a trend (p=0.077) (figure 38) 
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Figure 35.Frequency distribution of rs12979860 genotypes in individuals who attained 
RVR and in those who did not (RVR Rapid viral response) 
 
 
 
Figure 36.Distribution of the rs12979860 CC and non-CC genotypes in individuals who 
attained RVR and in those who did not (RVR Rapid viral response) 
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Figure 37.Frequency distribution of rs8099917 genotypes in individuals who attained 
RVR and in those who did not (RVR Rapid viral response) 
 
 
 
Figure 38.Distribution of the rs8099917 TT and non-TT genotypes in individuals who 
attained RVR and in those who did not (RVR Rapid viral response) 
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9. Association of the IL28B polymorphisms with EVR 
(a) rs 12979860 polymorphism 
The distribution of rs 12979860 CC/CT/TT genotypes was studied in individuals who 
attained EVR and those who did not (figure 39). 
Non-CC genotypes were found in 25% of individuals who did not attain EVR, compared to 
39% in those who attained EVR. There was no difference (p=1.00) (figure 40). 
 
(b) rs8099917 polymorphism 
Frequency distribution of rs8099917 TT/GT/GG genotypes was studied in individuals who 
attained EVR and those who did not (figure 41) 
Non TT genotypes were found in 29% of individuals who attained EVR and in none who did 
not attain EVR. The difference was not significant (p value= 0.553) (figure 42) 
Thus the IL28B polymorphisms were not found to be associated with EVR. 
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Figure 39.Frequency distribution of rs12979860 genotypes in individuals who attained 
EVR and in those who did not (EVR Early viral response) 
 
 
 
Figure 40.Distribution of the rs12979860 CC and non-CC genotypes in individuals who 
attained EVR and who did not (EVR Early viral response) 
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Figure 41.Frequency distribution of rs8099917 genotypes in individuals who attained 
EVR and in those who did not (EVR Early viral response) 
 
 
 
Figure 42.Distribution of the rs8099917 TT and non-TT genotypes in individuals who 
attained EVR and in those who did not (EVR Early viral response) 
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10. Association of the IL28B polymorphisms with ETR 
(a) rs 12979860 polymorphism 
The distribution of rs12979860 CC/CT/TT genotypes was studied in individuals who attained 
ETR and those who did not (figure 43). 
Non-CC genotypes were found  in 75% of individuals who did not attain ETR, compared to 
40% in those who attained ETR. However, the difference was not significant (p value=0.299) 
(figure 44). 
 
(b) rs8099917 polymorphism 
Frequency distribution of rs8099917 TT/GT/GG genotypes was studied in individuals who 
attained ETR and those who did not (figure 45). 
Non TT genotypes were found in 75% of individuals who did not attain ETR compared to 
31% in those who did. The difference was not significant (p value= 0.122) (figure 46). 
Thus IL28B polymorphisms were not found to be associated with ETR. 
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Figure 43.Frequency distribution of rs12979860 genotypes in individuals who attained 
ETR and in those who did not (ETR End of treatment response) 
 
 
 
Figure 44.Distribution of the rs12979860 CC and non-CC genotypes in individuals who 
attained ETR and in those who did not (ETR End of treatment response) 
0%
10%
20%
30%
40%
50%
60%
70%
CC CT TT
60%
31.43%
8.57%
25%
50%
25%
ETR attained
ETR not attained
60%
40%
ETR attained
CC Non-CC
25%
75%
ETR attained
CC Non-CC
P value=0.299 
106 
 
 
Figure 45.Frequency distribution of rs8099917 genotypes in individuals who attained 
ETR and in those who did not (ETR End of treatment response) 
 
 
 
Figure 46.Distribution of the rs8099917 TT and non-TT genotypes in individuals who 
attained ETR and who did not (ETR End of treatment response) 
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DISCUSSION 
Estimated to infect more than 185 million people worldwide(2) and over 10 million people in 
India (3), HCV is a common cause of post transfusion hepatitis in resource poor settings and 
in individuals at risk of unsafe injection practices. Tendency of the virus to cause persistent 
infection and the plethora of ensuing complications make treatment necessary. Currently, 
PEG-IFN plus RBV is the standard of care therapy for chronic hepatitis C. However, 
treatment is expensive and is marred by significant adverse effects, which may be severe 
enough to lead to withdrawal from treatment. This necessitates serial monitoring of viral load 
in patients on therapy at specified time points to assess and prognosticate the treatment 
response. In addition, the significance of viral and host factors which impact on severity of 
disease and response to treatment becomes immense. 
In this study we attempted to determine the frequency and distribution of IL28B gene 
polymorphisms in patients with chronic HCV infection and their association with response to 
IFN based treatment. Association of other host and viral factors with treatment response was 
also looked at.  
We recruited 57 HCV genotype 1, 3 and 4 infected patients, who were either on, or had 
completed IFN based treatment. The study patients hailed from various parts of the Indian 
subcontinent, including Bangladesh and Nepal in addition to many Indian states. Of the 57 
study patients, 12 (21%) were infected with HCV genotype 1, 43 (75%) with genotype 3 and 
2 (4%) with genotype 4. Genotype 6 infections were not included in the study owing to their 
rarity. The distribution of viral genotypes was in concordance with previous two studies from 
our institution where genotypes 3, 1 and 4 accounted for 64%, 26% and 8%;  and 62%, 19% 
and 6% HCV isolates respectively (7,51).  
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Assessment of virological response is recommended at specified time points of treatment; 
RVR at 4 weeks, EVR at 12 weeks, ETR at 24/48 weeks depending upon the genotype and 
SVR six months after end of treatment. Since ours is a tertiary care referral centre which 
caters to patients belonging to all parts of the country, the study participants were not 
available for sampling at all the recommended time points. Suitable treatment milestones 
were measured whenever possible. A proportion of our study participants (34 out of 57) 
completed follow up till the time of measurement of SVR during the course of the study, 
while the remaining 23 cases continue to be at different time points of follow up. A history of 
compliance to treatment was elicited from all patients, and cases with non-compliance were 
not included in the study. When analysed for the response rates, genotype 3 and 1 showed 
similar SVR rates of 54% and 57% respectively. 
The response rate of genotype 3 to interferon based therapy (54%) in the present study is 
lower than that seen in the western part of the world (88, 89), but is similar to the rates 
reported from our centre previously, when David et al. found SVR rate of  57% in HCV 
genotype 3 infections (124) However, this may be attributable to the referral bias of a tertiary 
care centre. Interestingly, studies from different parts of India have reported largely variable 
SVR rates in HCV genotype 3 infections. While high response rate (SVR=70%, n=356) has 
been seen in North Indian patients (18), a rate similar to ours (SVR=55%, n=83) has been 
found in a study involving patients from Eastern and North Eastern India (19). A smaller 
retrospective study from Mumbai, on the other hand, has found a very high response rate 
(SVR=87.5%, n=24), reflecting the huge heterogeneity in the Indian population (125). In a  
study involving 38 Asian and 66 Caucasian patients infected with HCV genotype 3, 
Freshwater et al. (126) found significantly lower response rates lower in Asians (42%) 
compared to Caucasians (62%). Asian patients included in this study were natives of the 
Indian subcontinent who had acquired infection with genotype 3 in their country of birth and 
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had later migrated to United Kingdom. These Asian patients had significantly greater fibrosis 
at presentation, were more frequently diabetic, and  had higher liver enzymes at baseline and 
throughout treatment. Baseline steatosis scores were available for half the patients in both the 
groups, and showed no difference. Non compliance to treatment was ruled out. However 
when a multivariate analysis of these factors was performed, nothing turned out to be 
significant, which the authors ascribed to the small numbers studied. The low response rates 
seen could be due to longer disease duration and advanced liver disease seen in Asians. On 
the contrary, SVR rates with genotype 3 infections from other parts of Asia have been much 
higher; 75% in China, and up to 90% in Korea and Taiwan (127). A multicentric trial 
comparing response rates in Asians (SVR= 65% n=52) vs whites (SVR=45% n=384) found 
Asian ethnicity to be highly predictive of viral clearance, irrespective of the infecting HCV 
genotype (127) .  
The response rate (57%) with genotype 1 is a little higher than earlier reported in large 
multicentric trials across the world (40 to 50%) (86,87). On the other hand, studies from Asia 
have shown high SVR rates; 61% in Japanese patients, 55 to 70% in Koreans and about 75% 
in Taiwanese (128). A few studies from India have shown tried to analyze the response rates 
in HCV genotype 1 infections. While a study from Mumbai (125) found SVR rate in 
genotype 1 to be 56% (n=16), another report from New Delhi (129) showed similar findings 
(SVR=55.5%, n=9). A multicentric study (130) involving 12 centres across 8 cities in the 
country recruited 27 HCV genotype 1 infected cases, of whom 20 were followed up till the 
time point of measurement of SVR. The response rate was found to be 60% (130) . However, 
larger studies are warranted to support these findings. 
Ever since four independent genome-wide association studies identified single nucleotide 
polymorphisms (SNPs) near the IL28B gene to be strong genetic determinants of treatment 
induced clearance of HCV (10–12,104), a multitude of studies have attempted to establish the 
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association. The two polymorphisms most strongly associated with treatment response are 
rs12979860 (C/C, C/T and T/T) and rs8099917 (T/T, T/G and G/G). The C/C genotype at 
rs12979860 and T/T genotype at rs8099917 have been shown to be associated with a good 
treatment response. While the impact of these polymorphisms on genotype 1 and 4 infections 
has been strongly established, their association with genotype 3 is considered weak (16). It is 
suggested that the favourable alleles C/C at rs12979860 and T/T genotype at rs8099917 are 
associated with lower intrahepatic levels of Interferon stimulated genes (ISGs) (106). 
Individuals with upregulated ISGs prior to treatment show poor outcome with Interferon 
based therapy, because the already induced ISGs fail to respond to exogenous interferon 
supplementation due to the saturated signalling pathways (131). Although an association 
between these polymorphisms and ISG levels has been seen, the exact mechanistic link is yet 
to be elucidated. Not only have these polymorphisms been linked with response to treatment, 
but their association with spontaneous clearance of the infection has also been described (14). 
The favourable genotypes at these loci have been found to be predictive of SVR in 
individuals who do not achieve RVR (132). The relevance of IL28B polymorphisms in the 
era of direct acting antivirals (DAA) is yet to be defined. Addition of DAA to interferon 
based regimens improves on-treatment viral kinetics, thus attenuating the impact of the SNPs, 
which also modulate on-treatment viral kinetics (133). The role of these polymorphisms in 
interferon free regimens is under investigation, while some preliminary reports show greater 
success rates with favourable IL28B genotypes (134). 
Genotyping of the 57 study participants was done to determine the polymorphisms at loci 
rs12979860 and rs8099917. The frequency distribution of rs12979860 CC/CT/TT genotypes 
was found to be 60%, 33% and 7% respectively. The distribution pattern we found was 
comparable to the previous studies from the country (17,18,19). Sivaprasad et al. (17) in their 
study on 220 uninfected individuals from Andhra Pradesh found the CC/CT/TT genotype 
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distribution to be 59%, 34% and 7% respectively. Gupta et al. (18) from New Delhi analysed 
the rs12979860 SNP in 356 HCV genotype 3 infected patients and 360 matched healthy 
controls. The CC/CT/TT genotype distribution was found to be 58%, 35%, and 7% 
respectively in cases of hepatitis C and 61%, 35%, and 4% respectively in uninfected 
controls, the difference not being significant. In another study by Firdaus et al. (19) involving 
400 HCV seropositive patients from Eastern and North Eastern India and 100 unrelated 
healthy controls, there was a greater distribution of the CC allele at the rs12979860 locus in 
both the groups. The frequency of CC/CT/TT genotypes was found to be 71%, 24% and 5% 
in cases, and 73%, 23% and 4% in controls respectively. All these studies have shown a 
much higher prevalence of CC allele at rs12979860 in the Indian subcontinent, when 
compared to the distribution in other ethnicities. In a landmark multicentric genome wide 
association study (111), the frequency distribution of CC/CT/TT genotypes was found to be 
37%, 51% and 12% respectively in Caucasians, 14%, 49% and 37% respectively in African-
Americans, 29%, 48% and 22% respectively in Hispanics. This stark difference in 
distribution of the SNP in various ethnicities is believed to partially account for the large 
differences seen in response rates in different populations (10), with Asians responding best 
to interferon based treatment, followed by Caucasians and then African Americans (97). 
On analysis of host genotype at rs8099917, we found that TT was the most common, present 
in 72% individuals, followed by GT in 23% cases and then GG in 5% individuals. The 
distribution pattern observed by us was similar to that seen by Firdaus et al. (19). They had 
found TT/GT/GG genotype frequency to be 77.50%, 15% and 7.50% respectively in HCV 
seropositive cases. In the control group genotype, TT was found in 70% individuals, followed 
by GT in 30%. There were no GG alleles in this group (19). There are no other studies from 
India determining the frequency distribution of this polymorphism. A large genome wide 
association study involving 1015 Caucasian chronic hepatitis C patients found the TT/GT/GG 
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distribution to be 58%, 37% and 5% respectively(104). In sharp contrast, in a study from 
Taiwan, the TT genotype was found in 85% of the cases, GT in 15% and GG in none (135). 
This suggests the prevalence of the TT genotype in Indians (72-77%) to be intermediate 
between Caucasians (58%) and East Asians (85%), which again mirrors the comparative rates 
of response seen in these populations.  
To analyze the impact of the two polymorphisms on response to treatment, we compared the 
distribution of the rs12979860 CC/CT/TT and rs8099917 TT/GT/GG genotypes in 
responders and non-responders. Both non-responders and relapsers were grouped together as 
non-responders for the sake of the analysis. The CC genotype at rs12979860 was observed in 
84% of responders compared to only 40% in the non-responders, suggesting that the 
polymorphism is significantly associated with SVR. On analysis of the rs8099917 
polymorphisms, TT genotype was found in 84% of those who attained SVR compared to 
53% in those who did not. Though the difference between the two groups was not statistically 
significant, a trend was seen. The impact of these polymorphisms on RVR, EVR and ETR 
was also studied. No association of the SNPs was seen with EVR and ETR. However, CC 
genotype at rs12979860 was significantly associated with RVR, and TT genotype at 
rs8099917 again showed a trend. Thus we inferred that rs12979860 polymorphism influences 
treatment response in chronic hepatitis C patients and the CC genotype is a predictor of RVR 
and SVR. The association with rs8099917 polymorphism could not be established, though 
there was a trend. 
Although the association of these polymorphisms with genotype 1 HCV has been 
documented in several studies from many regions of the globe (109,110), the association with 
genotype 3 has been controversial, with studies yielding contrasting results. Comparing our 
results with the available Indian literature, our findings reiterated the conclusions of Gupta et 
al. (18) and Firdaus et al. (19) with regard to the rs12979860 polymorphisms. However, we 
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did not find a significant association of the rs8099917 polymorphism with response to 
treatment, unlike Firdaus et al.(19). The limited numbers analyzed in our study (n=34) might 
be a reason for masking of the association.  
We also attempted to analyze the association of other host and viral factors on SVR. Patients 
were categorised based on age (≤40 years vs. >40 years), gender, body mass index (≤ 25 vs. 
>25), diabetic status, pre-treatment viral load (≤600,000 vs. >600,000 IU/ml), ALT levels 
(≤105 vs. >105 U/ml) and treatment modality (PEG-INF vs. standard IFN). None of these 
variables turned out to be significant in our study. While younger patients have shown better 
treatment response in large multicentric studies (87,89), the association with female gender 
has been inconsistent (9,67,87,89). A lower body weight has been found to be predictive of 
SVR (87,89). Diabetes mellitus has emerged as a cofactor in failure to achieve SVR (101).  
Lower baseline viral loads have been associated with greater response rates (83,86). We were 
not able to establish an association of treatment response with any of these factors. A 
previous study from our centre (124) also attempted to study the effect of age, gender and 
pre-treatment viral load on SVR, but failed to find any association. Similarly Gupta et al. (18) 
did not find age, gender, body mass index and base line viral load to influence SVR. 
Diabetes mellitus has been found to be a predictor of non response to interferon based 
treatment in patients with chronic hepatitis C. In a case control study (101), 61 diabetic and 
122 non-diabetic chronic HCV patients were treated with standard regimen of PEG-INF 
/RBV as per the infecting viral genotype. The diabetic patients were older, had significantly 
high body mass index, greater steatosis and advanced hepatic fibrosis, and showed a 
significantly lower SVR rates (23%) compared to the compared to non-diabetic HCV patients 
(46%). It is hypothesised that hyperinsulinemia associated with type 2 diabetes accelerates 
progression of liver fibrosis. Of the 34 patients analyzed in our study, 9 were diabetics. There 
was no difference in the response rate in diabetics and non diabetics. 
114 
 
The association between baseline ALT levels and viral response in HCV infection is not as 
distinct as in chronic hepatitis B infection (97). While Fried et al.(87) could not find an 
association of liver enzymes with SVR, Shiffman et al.(89) observed such a correlation in 
HCV genotype 2 and 3 infected patients. In our study, 21 out of 34 patients had pre-treatment 
ALT levels greater than 105 U/L, of whom 16 achieved SVR (76%). Of the 8 patients who 
had ALT levels ≤ 105 U/L, 3 achieved SVR (37.5%). The data was not available for 5 
patients, as they had been treated at some other centre and had been referred to us later. 
Though the difference between the two groups was not statistically significant, a trend was 
observed (p=0.08). In a previous report from our centre (124), baseline ALT levels were not 
found to be associated with treatment response. Similarly, Gupta et al.(18) did not such an 
association, though their cut off was 100U/L. 
Modification of standard interferon by attachment of a polyethylene glycol moiety has been 
reported to improve virological response rates by over 10% due the improvement of the 
pharmacokinetic profile (74,84) . Of the 34 patients we followed up, 21 were on PEG-INF 
and RBV combination therapy while the remaining 13 patients were on treatment with a 
combination of standard IFN and RBV. Of the 21 patients, 10 achieved SVR while 9 of the 
13 receiving standard interferon achieved SVR. No difference was found between the two 
groups in terms of SVR rates. This is in keeping with our previous experience, when David et 
al.(124) in their retrospective analysis of HCV genotype 3 infected patients did not find any 
difference in the response rates between individuals treated with standard IFN vs. PEG-INF. 
Studies with greater sample sizes are needed to bring out the picture more clearly. 
Another variable analyzed for effect on SVR was RVR. We found RVR to be a strong 
predictor of SVR. In our analysis of the 34 patients who were followed upto 6 months after 
cessation of therapy, RVR rates were found to be 71%. RVR was achieved in 100% of the 
patients who were treatment responders, in sharp contrast to only 20% in patients who turned 
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out to be treatment non-responders. RVR is considered one of the strongest predictors of 
sustained viral clearance. In a large randomized controlled trial by Ferenci and colleagues  
involving (136) 1121 patients, RVR was found to be highly predictive of long term response 
in patients treated with PEG-INF plus placebo, PEG-INF plus RBV and standard IFN plus 
RBV. Gupta et al. (18) and Firdaus et al. (19) also replicated the finding that RVR was 
strongly associated with response to interferon based therapy for chronic hepatitis C. While 
IL28B genotype is identified as the strongest pre-treatment predictor of sustained viral 
clearance, RVR is known to be the key on-treatment response predictor(132). 
Advanced liver fibrosis and cirrhosis are major predictors of non-response to treatment, 
across all viral genotypes. The impact of these SNPs on progression of the liver disease is not 
clearly established, though an association has been seen (19). Our study did not address the 
histopathological features seen on liver biopsy, and their association with treatment response. 
Liver biopsy, being an invasive procedure, was not performed on any of the 34 patients we 
analyzed. If available, liver biopsy samples could provide not only the histopathological 
picture, but would also help in determining the expression levels of intahepatic ISGs, which 
would predict the response to interferon based therapy, as discussed above. 
We attempted a multivariate analysis of the factors impacting response but, we did not find 
any independent factors associated with sustained viral response. This is largely attributable 
to the limited numbers studied, which was primarily due to the time frame for completion of 
this study and absence of regular follow up in many patients  due to the long distances 
patients have to travel to come for review to our tertiary care centre. A larger study will be 
required to analyze the effect of these host and viral factors on treatment response. 
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CONCLUSION 
In this study, we determined the frequency and distribution of IL28B polymorphisms at loci 
rs12979860 and rs8099917 in 57 HCVinfected patients. SVR rates in genotype 1 and 3 were 
analyzed and compared. We studied the impact of IL28B single nucleotide polymorphisms 
on response to treatment in chronic hepatitis genotype 1 and 3 infections. We also studied the 
association of other factors like age, gender, body mass index, diabetes, rapid viral response, 
pre-treatment viral load, baseline ALT levels and treatment modality (pegylated vs. standard 
interferon) with sustained virological response.  
The CC allele at rs12979860 and TT at rs8099917 were found in majority of the cases (60% 
and 72% respectively). We found similar response rates in HCV genotype 1 and 3 infections 
(57% and 54% respectively).The CC genotype at rs12979860 loci was found to be associated 
with sustained viral response. No association was found between rs8099917 polymorphism 
and treatment response. Rapid viral response was found to be most predictive of sustained 
viral clearance. An association could not be found with younger age, female gender, lower 
body mass index, non-diabetic state, lower pre-treatment ALT levels, lower baseline viral 
loads and sustained response to anti-viral therapy. The response rate seen with PEG-IFN was 
the same as that with standard interferon therapy. The two polymorphisms were not found to 
be associated with EVR and end of treatment response. However an association of CC 
genotype at rs12979860 with RVRwas seen. 
Ours is the first attempt from the country to study the impact of IL28B polymorphisms on 
HCV genotype 1 infected patients in addition to genotype 3. We intend to continue the study 
on larger number of samples to validate our findings and to bring out the associations more 
strongly.   
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                                                 PATIENT INFORMATION SHEET 
Study title 
 Study of the association of IL-28B polymorphisms with virological markers and treatment 
response in patients with hepatitis C virus  infection 
 
Purpose of the study: 
Hepatitis C is a virus which causes infection of the liver, which can often progress to chronic 
liver disease, sometimes resulting in liver failure and liver cancer. It is treated with drugs called 
interferons and ribavirin, which are expensive and also have some significant side effects. 
However, chronic nature of the infection makes treatment important.  
The severity of the disease and the response to treatment depends on a number of viral and 
human factors. One such human factor is a gene called IL 28B. There are different genotypes the 
IL 28B gene which predict the response to treatment. 
In this study we aim to identify the genotype of IL 28B gene present in patients with hepatitis C 
virus infection, and correlate it with treatment response. 
 
      Description of the procedure: 
Relevant patient details will be recorded. Blood sample collected in the department of Clinical 
Virology as a part of the routine testing will be used to carry out the additional tests in the 
laboratory. 
 
Risks or discomfort to the Subject: 
As no additional procedures will be performed on the participants, the risks are negligible. The 
participant will not incur any expense for the extra tests done on the blood sample. The cost of 
the tests will be borne by the research sponsors. 
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Benefits of the study: 
The information gathered from the study will largely help in the prediction of the treatment 
response of hepatitis C. 
 
Confidentiality: 
Only the investigators of this study will be able to access the patient‟s medical records and the 
results of the test. Patients identity will not be revealed in any form or release to third parties or 
published. 
       Participation:   
The patient‟s participation in the study entirely voluntary and the patient is free to withdraw 
from the study at any time, without stating any particular reason. Refusal to participate or 
withdrawal from the study will not involve any penalty or loss of benefits to which the patient 
is otherwise entitled 
 
Kindly note: 
a. Termination - the patient‟s participation in the study may be terminated if the patient has 
illnesses which may interfere with the results of the study 
b. No additional costs to the patient from participation in the study  
 
Kindly ask questions and clear doubts before participation as some of the medical terms may 
not be familiar to you. 
 
Contact person: Dr Pragya Ranjan, PG Registrar, Department of Clinical Microbiology  
Phone no:0416-228258 
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INFORMED CONSENT FORM 
(For participation in a research study) 
 
  Study Title: Study of the frequency and distribution of IL 28B polymorphisms in hepatitis C 
virus infected patients and their association with virological markers and treatment response 
 
Study Number: 
Date of Birth / Age: _______ 
 
I________________________________________________ 
 
 son/daughter of ___________________________________ 
(i) I confirm that I have read and understood the information sheet dated _________ for 
the above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
(iii) I understand that those conducting this study, the Ethics Committee and the regulatory 
authorities will not need my permission to look at my health records both in respect of 
the current study and any further research that may be conducted in relation to it, even 
if I withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or published. [ 
] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: 
__________________________________ 
Date: _____/_____/______ 
Signatory‟s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator‟s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name of the Witness: ______________________________ 
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